var title_f5_33_5648="MP joint swelling";
var content_f5_33_5648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metacarpophalangeal (MP) joint swelling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is asked to make a partial fist and the MP joints are inspected for swelling. Swelling of multiple MP joints is recognized in this patient by loss of the normal hills and valleys between the knuckles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5648=[""].join("\n");
var outline_f5_33_5648=null;
var title_f5_33_5649="Asymmetric leg folds";
var content_f5_33_5649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Asymmetric leg folds",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 655px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Asymmetry of the thigh or popliteal creases is suggestive of developmental dysplasia of the hip (DDH), with the abnormality on the side where the crease is most proximal. Asymmetry of the thigh folds or popliteal creases is not helpful in cases of bilateral DDH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5649=[""].join("\n");
var outline_f5_33_5649=null;
var title_f5_33_5650="Ht age girls z 2 5";
var content_f5_33_5650=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Height-for-age girls: 2 to 5 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 406px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5650=[""].join("\n");
var outline_f5_33_5650=null;
var title_f5_33_5651="Patient information: Giving your child insulin (The Basics)";
var content_f5_33_5651=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16600\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/28/5571\">",
"         Where to give your child an insulin shot",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/58/10145\">",
"          How to give an insulin shot",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/52/37699\">",
"         Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/26/39331\">",
"         Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/25/36243\">",
"         Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/11/38066\">",
"         Patient information: Managing diabetes in school (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/47/6899\">",
"         Patient information: Should I switch to an insulin pump? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/40/22144\">",
"         Patient information: The ABCs of diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/58/28579\">",
"         Patient information: Using insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/31/35317\">",
"         Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/43/39603\">",
"         Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Giving your child insulin (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/giving-your-child-insulin-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2056286\">",
"      <span class=\"h1\">",
"       What is insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Insulin is a hormone that helps the body use sugar. Children with type 1 diabetes (or &ldquo;type 1 diabetes mellitus&rdquo;) need to take insulin as a medicine to lower their body&rsquo;s blood sugar level.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056301\">",
"      <span class=\"h1\">",
"       Are there different types of insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some types of insulin start working faster than others or last for a longer amount of time. Your child will need different types of insulin each day. That way, his or her body can have the right amount of insulin all day and night.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056316\">",
"      <span class=\"h1\">",
"       How many times a day does my child need insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your child&rsquo;s treatment plan. Your child will need insulin doses at different times of the day, including before he or she eats meals and snacks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056331\">",
"      <span class=\"h1\">",
"       How much insulin should I use?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For some doses, your child&rsquo;s doctor or nurse will tell you how much insulin to give your child. For other doses, you will need to figure out the amount of insulin to give to your child. The amount of insulin will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What your child will eat at the next meal",
"       </li>",
"       <li>",
"        How much exercise your child plans to do",
"       </li>",
"       <li>",
"        What your child&rsquo;s blood sugar level is",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You will need to change your child&rsquo;s insulin dose at certain times, such as when:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your child gets sick or has surgery",
"       </li>",
"       <li>",
"        You travel or your child&rsquo;s routine changes",
"       </li>",
"       <li>",
"        Your child grows older and gets bigger",
"       </li>",
"       <li>",
"        Your child does certain activities, such as camps or sports",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your child&rsquo;s doctor or nurse will tell you how to change the insulin dose during these times.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056346\">",
"      <span class=\"h1\">",
"       How do I give my child insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Insulin usually comes in the form of a shot (called an &ldquo;injection&rdquo;). When your child is young, you will need to give him or her insulin shots. When your child gets older, he or she can learn to give the insulin shots.",
"     </p>",
"     <p>",
"      Your child&rsquo;s doctor or nurse will teach you how to give your child an insulin shot. You will need to use a needle and syringe to draw up the right amount of insulin from a small bottle. Then you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Choose a part of the body &ndash; You can give insulin shots in different parts of the body (",
"        <a class=\"graphic graphic_figure graphicRef57381 \" href=\"UTD.htm?5/28/5571\">",
"         figure 1",
"        </a>",
"        ). It&rsquo;s best to change the part of the body each time you give the shot.",
"       </li>",
"       <li>",
"        Clean that area, if your doctor or nurse recommends it. Some people use an alcohol wipe.",
"       </li>",
"       <li>",
"        Pinch up some skin and quickly insert the needle (",
"        <a class=\"graphic graphic_figure graphicRef80789 \" href=\"UTD.htm?9/58/10145\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Push the plunger down all the way and then count to 5.",
"       </li>",
"       <li>",
"        Let go of the skin and remove the needle.",
"       </li>",
"       <li>",
"        Throw out the used needle and syringe in a container that is made for used needles &ndash; Do not throw out used needles and syringes in the regular trash.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Insulin can also come in other forms. Your child can get insulin from:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An insulin pump &ndash; An insulin pump is a device that slowly delivers insulin to the body. The insulin goes from the pump, through a thin tube, and into the body through a tiny needle put under the skin. Insulin pumps work by giving small doses of fast-acting insulin throughout the day and night. Before meals and snacks, you or your child can use the pump to give extra insulin (called a &ldquo;meal bolus&rdquo;).",
"       </li>",
"       <li>",
"        A &ldquo;pen injector&rdquo; &ndash; A pen injector is a device that looks like a pen and has insulin in it. A pen injector uses a new needle for each insulin dose.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056361\">",
"      <span class=\"h1\">",
"       How do I know if I&rsquo;m giving my child the right amount of insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To know if you are giving your child the right amount of insulin, you can check your child&rsquo;s blood sugar level.",
"     </p>",
"     <p>",
"      If you use too much insulin, your child&rsquo;s blood sugar level can get too low. If you don&rsquo;t use enough insulin, your child&rsquo;s blood sugar level can get too high. Levels that are too low or too high can cause serious problems.",
"     </p>",
"     <p>",
"      Checking your child&rsquo;s blood sugar level can also help you choose your child&rsquo;s next insulin dose. To check your child&rsquo;s blood sugar level, you can use a device called a &ldquo;blood glucose meter.&rdquo; Your child&rsquo;s doctor or nurse will show you how to use it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2056376\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=see_link\">",
"       Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=see_link\">",
"       Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=see_link\">",
"       Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=see_link\">",
"       Patient information: Managing diabetes in school (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=see_link\">",
"       Patient information: The ABCs of diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       Patient information: Using insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=see_link\">",
"       Patient information: Should I switch to an insulin pump? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/33/5651?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16600 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5651=[""].join("\n");
var outline_f5_33_5651=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056286\">",
"      What is insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056301\">",
"      Are there different types of insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056316\">",
"      How many times a day does my child need insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056331\">",
"      How much insulin should I use?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056346\">",
"      How do I give my child insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056361\">",
"      How do I know if I&rsquo;m giving my child the right amount of insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2056376\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16600\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/28/5571\">",
"      Where to give your child an insulin shot",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/58/10145\">",
"       How to give an insulin shot",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=related_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=related_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=related_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=related_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=related_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_33_5652="Echo MVG normal HHD";
var content_f5_33_5652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examples of echocardiographic transmitral flow patterns and myocardial velocity gradients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top panel (A) shows transmitral flow patterns and the bottom panel shows myocardial velocity gradients (MVGs) from normal subjects, patients with hypertensive heart disease (HHD) and patients with dilated cardiomyopathy (DCM). In HHD, there is a decrease in E and E/A and an increase in deceleration time of the early diastolic filling velocity (DcT). These variables were not altered in DCM compared to normals. In contrast, the peak MVGs were lower in HHD and DCM compared to normals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Shimizu, Y, Uematsu, M, Shimizu, H, et al. J Am Coll Cardiol 1998; 32:1418.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5652=[""].join("\n");
var outline_f5_33_5652=null;
var title_f5_33_5653="Amoxicillin and clavulanate potassium: Patient drug information";
var content_f5_33_5653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amoxicillin and clavulanate potassium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     see \"Amoxicillin and clavulanate potassium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     see \"Amoxicillin and clavulanate potassium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amoclan;",
"     </li>",
"     <li>",
"      Augmentin ES-600&reg;;",
"     </li>",
"     <li>",
"      Augmentin XR&reg;;",
"     </li>",
"     <li>",
"      Augmentin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amoxi-Clav;",
"     </li>",
"     <li>",
"      Apo-Amoxi-Clav&reg;;",
"     </li>",
"     <li>",
"      Clavulin&reg;;",
"     </li>",
"     <li>",
"      Novo-Clavamoxin;",
"     </li>",
"     <li>",
"      ratio-Aclavulanate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amoxicillin, clavulanate potassium, any penicillin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug caused liver problems before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700924",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Augmentin XR&trade;: If you have very bad kidney disease or are on dialysis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Scored long-acting product: Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696158",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unscored long-acting product: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Do not freeze. Throw away any part not used after 10 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10900 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5653=[""].join("\n");
var outline_f5_33_5653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134614\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134615\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026682\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026681\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026686\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026687\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026689\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026684\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026685\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026690\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026691\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=related_link\">",
"      Amoxicillin and clavulanate potassium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=related_link\">",
"      Amoxicillin and clavulanate potassium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_33_5654="2 to 1 block below His";
var content_f5_33_5654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    2:1 infra-Hisian block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 320px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The baseline 12-lead electrocardiogram in this patient demonstrated sinus rhythm with 2:1 AV block with prolonged AV conduction, an anterior wall myocardial infarction, right bundle branch block, and left anterior fascicular block. All 12 surface leads are shown. Representative intracardiac tracings are the distal His bundle electrogram (HIS d) and the proximal His bundle electrogram (HIS p). Every other atrial depolarization is followed by a His, but no ventricular depolarization (arrows) indicating infra-Hisian block. Note the normal A-H intervals and prolonged H-V intervals on conducted beats.",
"    <div class=\"footnotes\">",
"     A: atrial depolarization; AV: atrioventricular; H: His bundle depolarization; V: ventricular depolarization.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph J Germano, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5654=[""].join("\n");
var outline_f5_33_5654=null;
var title_f5_33_5655="Acute lumbosacral radiculopathy: Prognosis and treatment";
var content_f5_33_5655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute lumbosacral radiculopathy: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5655/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5655/contributors\">",
"     Kerry Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5655/contributors\">",
"     Philip S Hsu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5655/contributors\">",
"     Carmel Armon, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5655/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5655/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5655/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5655/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/33/5655/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral radiculopathy is a condition in which a disease process affects the function of one or more lumbosacral nerve roots. The most common cause is structural &mdash; disc herniation or degenerative spinal stenosis &mdash; leading to root compression.",
"   </p>",
"   <p>",
"    This topic will review the prognosis and treatment of lumbosacral radiculopathy, focusing on the acute period (up to four weeks). Other clinical aspects of lumbosacral radiculopathy and the management of lumbar spinal stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22776?source=see_link\">",
"     \"Lumbar spinal stenosis: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of subacute and chronic low back pain is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link\">",
"     \"Subacute and chronic low back pain: Surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While acute lumbosacral radiculopathy is often extremely painful, the likelihood of spontaneous improvement is thought to be high when the cause is disc herniation or lumbar spinal stenosis due to degenerative arthritis. However, natural history data for lumbosacral radiculopathy are limited.",
"   </p>",
"   <p>",
"    Some insight can be gained from placebo arms of randomized trials. In this regard, a trial of 208 patients with acute L5",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    S1 radiculopathy found no significant difference in outcome for those assigned to nonsteroidal antiinflammatory treatment or to placebo at four weeks, and most patients had a satisfactory recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/1\">",
"     1",
"    </a>",
"    ]. At three months, approximately 30 percent of patients in both groups still had complaints of back pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be helpful to group patients with acute lumbosacral radiculopathy into one of three general categories based upon radicular symptoms and signs. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sensory loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pain without a motor deficit",
"     </li>",
"     <li>",
"      Sensory loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pain with a mild motor deficit",
"     </li>",
"     <li>",
"      Sensory loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pain with a marked motor deficit (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link&amp;anchor=H20#H20\">",
"       \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\", section on 'Severity'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The objectives of treatment are to ameliorate pain (symptomatic treatment), and to address the specific underlying process (mechanism-specific treatment) if necessary.",
"   </p>",
"   <p>",
"    Since lumbosacral radiculopathy due to disc herniation is typically self-limited, symptomatic treatment is used to tide the patient over the acute period. In patients who have underlying lumbar spinal stenosis due to degenerative arthritis, the radicular symptoms can wax and wane, although the long-term prognosis may be less favorable than a disc herniation.",
"   </p>",
"   <p>",
"    In order to reduce the risk of recurrent symptoms, a program of weight reduction should be encouraged in patients with elevated body mass index.",
"   </p>",
"   <p>",
"    Mechanism-specific treatment is indicated for progressive neurologic compromise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent symptoms that are unresponsive to time and conservative measures. Surgery for disc herniation and lumbar spinal stenosis is most commonly performed because of persistent symptoms or progressive neurological impairment. In the setting of progressive neurological impairment, rapid surgical consultation should be considered.",
"   </p>",
"   <p>",
"    Neoplastic or infectious etiologies of radiculopathy require prompt mechanism-specific treatment. Though rare, cauda equina syndrome represents a true surgical emergency where decompression should be performed within 24 hours, and within 12 hours if possible.",
"   </p>",
"   <p>",
"    The diagnosis and evaluation of suspected lumbosacral radiculopathy is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link&amp;anchor=H21#H21\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral radiculopathy is often extremely painful. Analgesic medications such as nonsteroidal antiinflammatory drugs or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and activity modification are the mainstay of treatment. Physical therapy is often tried for patients with mild to moderate persistent symptoms, but evidence of effectiveness is lacking.",
"   </p>",
"   <p>",
"    The use of opioids and muscle relaxants to treat acute, severe low back pain is common in clinical practice. Opioids are most often prescribed for patients with radiculopathy and severe pain who have inadequate relief with non-narcotics. However, opioids should be limited to short-term use only.",
"   </p>",
"   <p>",
"    Both benzodiazepines and antispasmodic agents (classified as muscle relaxants) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    are commonly used in painful radiculopathy. However, their efficacy has not been demonstrated, and they would be expected to have little benefit for pain arising from the compressed nerve root. In our clinical experience, muscle relaxants do not provide a significant benefit over nonnarcotic analgesic medications. Using opioids combined with muscle relaxants is risky because of the additive sedating effects.",
"   </p>",
"   <p>",
"    The utility of systemic glucocorticoids and epidural glucocorticoids is limited, as discussed below.",
"   </p>",
"   <p>",
"    Unfortunately, interpretation of the available treatment data is confounded by several issues, which include the benign or self-limited course of lumbosacral radiculopathy, the role of placebo effect, and social factors. These issues impede the selection of effective treatments, particularly for patients who fail to gain complete relief despite a four week course of analgesic medication, activity modification, and physical treatments. It is not known whether four additional weeks of the same conservative treatments would be as beneficial as potential alternatives, such as systemic and epidural glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonnarcotic analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience suggests that short-term treatment with either a nonsteroidal antiinflammatory drug (NSAID) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is useful for patients with acute lumbosacral radiculopathy. NSAIDs may be preferred for patients without significant renal, gastric, or cardiovascular comorbidity, while acetaminophen can be used for patients without hepatic compromise who cannot tolerate NSAIDs.",
"   </p>",
"   <p>",
"    However, the effectiveness of NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for acute lumbosacral radiculopathy has not been established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no randomized controlled trials evaluating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      for acute low back pain or acute lumbosacral radiculopathy.",
"     </li>",
"     <li>",
"      The available clinical trial evidence regarding the benefit of NSAIDs for acute lumbosacral radiculopathy is limited and conflicting. Some show benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/2\">",
"       2",
"      </a>",
"      ] and others no benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/3\">",
"       3",
"      </a>",
"      ]. In a 2008 systematic review, two of these trials were identified as the only ones reporting sufficient data on pain intensity in patients with acute low back pain and sciatica for pooled analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/4\">",
"       4",
"      </a>",
"      ]. Since the two trials had conflicting results, the pooled analysis found no statistical difference in effect between NSAIDs and placebo (weighted mean difference [WMD] -0.16, 95% CI -11.92 to 11.52) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/4\">",
"       4",
"      </a>",
"      ]. The included trials suffered from methodologic problems with unclear allocation concealment and randomization procedures. Similarly, a 2012 meta-analysis identified three trials [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/1,2,5\">",
"       1,2,5",
"      </a>",
"      ] comparing NSAIDS with placebo for acute sciatica [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/6\">",
"       6",
"      </a>",
"      ]. The pooled analysis showed only a small and statistically nonsignificant treatment effect for improvement in pain. The quality of evidence for this analysis was considered low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Activity modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activity modification is as important as analgesics treatment in the management of acute radiculopathy. The goals are to lessen nerve root impingement and to avoid activities that exacerbate pain.",
"   </p>",
"   <p>",
"    Patients often identify pain-relieving positions for themselves. Some individuals report that semi-sitting, reclining, or lying in certain positions in bed provide meaningful pain relief. Others find that recumbency in bed is associated with increased pain. Such patients may prefer to be up and around, even going about light work duties.",
"   </p>",
"   <p>",
"    Modification or avoidance of activity does not imply prolonged complete bed rest. When the acute symptoms decrease, we recommend resuming modest physical activity as tolerated. Randomized trials of patients with acute lumbosacral radicular syndromes have found no significant difference in outcome for treatment with bed rest versus watchful waiting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/7\">",
"     7",
"    </a>",
"    ] or bed rest versus physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/8\">",
"     8",
"    </a>",
"    ]. Similarly, a systematic review of these studies found no benefit for bed rest [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical or manual therapies are often tried for patients with persistent symptoms that are mild or moderate in nature. However, few studies have evaluated physical or manual therapies for acute radiculopathy, and there is no convincing evidence that such treatments are effective for this indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of acute low back pain\", section on 'Exercise and other physical modalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal timing of referral to physical therapy remains unclear, as does the optimal frequency of visits and duration of therapy. In general, physical therapy in the first one to two weeks is not recommended because patients with mild symptoms are likely to improve on their own while patients with very severe symptoms cannot participate in exercise therapy. Given the generally favorable natural history of acute lumbosacral radiculopathy, it is reasonable to delay physical therapy until symptoms have persisted for three weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid therapy is commonly considered for patients with severe pain that is inadequately controlled with nonsteroidal antiinflammatory drugs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . However, no randomized controlled trials have evaluated opioids for acute lumbosacral radiculopathy. Similarly, there are no data to suggest that chronic opioid use is of value for radiculopathy.",
"   </p>",
"   <p>",
"    Adverse effects of opiates include sedation, confusion, nausea, and constipation. Respiratory depression is an issue at higher doses but rarely at the doses used for acute low back pain. As with other medications, older patients are more susceptible to these adverse effects.",
"   </p>",
"   <p>",
"    In the absence of definitive data, use of opiates for low back pain is a matter of clinical judgment. Some experts oppose the use of opiates for acute radiculopathy given the lack of proven efficacy, the potential for serious side effects, and the potential for misuse and abuse.",
"   </p>",
"   <p>",
"    When prescribed, opioids should be used on a fixed schedule, rather than as-needed, and only for a limited and clearly defined period of time without reevaluation, generally at two week follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the clinical experience of some of the authors, systemic glucocorticoid treatment may provide partial pain relief for select patients with acute lumbosacral radiculopathy. However, it has not been evaluated for this indication in large randomized controlled trials. The available evidence from small trials suggests that systemic glucocorticoid therapy has either limited benefit or no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. A 2007 practice guideline from the American Pain Society and the American College of Physicians reviewed four small trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/11-14\">",
"     11-14",
"    </a>",
"    ] and concluded that systemic glucocorticoids are ineffective for low back pain with sciatica (ie, with radicular symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/10\">",
"     10",
"    </a>",
"    ]. A 2012 meta-analysis of three small trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/11,15,16\">",
"     11,15,16",
"    </a>",
"    ] in patients with acute sciatica concluded that pooled estimates showed no effect of glucocorticoids in the immediate term (two weeks or less after randomization) but a significant benefit of glucocorticoids in the short term (two weeks to three months from randomization) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/6\">",
"     6",
"    </a>",
"    ]. The quality of evidence was considered moderate.",
"   </p>",
"   <p>",
"    Acknowledging that any benefit is likely modest, one author of this topic sometimes employs a course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60 to 80 mg daily) for five to seven days for patients with acute lumbosacral radiculopathy who do not respond well to analgesics and activity modification. This is followed by a rapid taper to discontinuation over the following 7 to 14 days. However, the other authors generally do not use systemic glucocorticoids in this setting.",
"   </p>",
"   <p>",
"    Major side effects associated with systemic glucocorticoids include elevated blood pressure, mood disorders, psychosis, insomnia, gastritis, ulcer formation, gastrointestinal bleeding, hyperglycemia, bone loss, and heightened risk of typical infections. Some of these side effects are both dose and duration dependent, and are more likely to occur with long-term glucocorticoid use.",
"   </p>",
"   <p>",
"    Patients taking glucocorticoids in combination with NSAIDs may require prophylaxis against gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Epidural glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural glucocorticoid injections may provide modest transient benefit for amelioration of back and leg pain in patients with acute lumbosacral radiculopathy. However, they provide no benefit beyond three months.",
"   </p>",
"   <p>",
"    Based mainly upon evidence from four high-quality randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/17-20\">",
"     17-20",
"    </a>",
"    ], a 2007 systematic review concluded that epidural glucocorticoid injections may be more effective than placebo for short-term improvement in chronic radicular lumbosacral pain when assessed two to six weeks after injection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the average effect size was small and was less than the value considered clinically meaningful in most of the included trials. In addition, benefit was no longer present at three months or later. A 2012 systematic review and meta-analysis of 23 trials reached similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/22\">",
"     22",
"    </a>",
"    ]. The trials included the 2007 and 2012 reviews enrolled patients with mainly subacute (eg, &gt;6 weeks) or chronic radicular symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, no randomized trials have compared epidural glucocorticoid injections with continued analgesic treatment for lumbosacral radiculopathy.",
"   </p>",
"   <p>",
"    Side effects of epidural glucocorticoid injections are typically minor and transient [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/21\">",
"     21",
"    </a>",
"    ]. The most common is headache. Major complications are rare but include aseptic and bacterial meningitis, arachnoiditis, epidural abscess, and conus medullaris syndrome.",
"   </p>",
"   <p>",
"    Radiographically-guided transforaminal placement of the injection does not appear to result in better outcomes compared to a \"blind\" approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the available evidence suggests that the benefit of epidural glucocorticoid injections is modest and transient, and may not be clinically meaningful. Some evidence suggests that patients who receive the injections may be worse off at three and six months than those who do not.",
"   </p>",
"   <p>",
"    Given the usually self-limited natural history of acute lumbosacral radiculopathy and the availability of alternatives, epidural glucocorticoid injections are not recommended during the acute phase of lumbosacral radiculopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of surgery for symptomatic lumbar disc herniation is to relieve symptoms due to compression or inflammation of affected nerve roots. The surgery involves either partial or complete removal of the herniated disc. The utility of surgery for symptomatic lumbar disc prolapse is reviewed here briefly and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link&amp;anchor=H6#H6\">",
"     \"Subacute and chronic low back pain: Surgical treatment\", section on 'Lumbar disc prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to have surgery requires assessing whether a clinically meaningful reduction in pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disability is more likely to occur spontaneously or with surgery. The patient's course with regard to pain and neurologic deficits (for better or worse) over time will help inform the final decision.",
"   </p>",
"   <p>",
"    There is no evidence that early referral for surgery improves outcome in patients with lumbar disc prolapse and radiculopathy who do not have severe or progressive neurologic deficits. Most studies comparing surgery and nonsurgical care have included patients with at least six weeks of symptoms. In these studies, patients who undergo discectomy have a more favorable outcome than nonsurgically treated patients at short-term follow-up, but outcomes are equivalent at one to two years.",
"   </p>",
"   <p>",
"    Current guidelines from the American Pain Society recommend that clinicians discuss risks and benefits of surgery with patients who have persistent, disabling radiculopathy due to a herniated lumbar disc [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5655/abstract/23\">",
"     23",
"    </a>",
"    ]. The guidelines note that benefits are moderate on average, and decrease over time compared to patients who do not choose to have surgery.",
"   </p>",
"   <p>",
"    There is no clear correlation between the size of disc herniation or nerve compression and the amount of spinal nerve root injury. Small compressive lesions can at times produce severe, irreversible nerve damage if they affect arterial blood supply to the nerve. An ischemic nerve lesion, though severe, would not be likely to improve after removal of the compressive lesion.",
"   </p>",
"   <p>",
"    For patients with persistent (at least six weeks duration), disabling lumbar radicular symptoms who are good surgical candidates and desire surgery, either open discectomy or microdiscectomy are reasonable options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link&amp;anchor=H6#H6\">",
"     \"Subacute and chronic low back pain: Surgical treatment\", section on 'Lumbar disc prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=see_link\">",
"       \"Patient information: Herniated disc (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/8/32898?source=see_link\">",
"       \"Patient information: Radiculopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute lumbosacral radiculopathy caused by disc herniation or foraminal stenosis is often extremely painful, but the likelihood of spontaneous improvement is high. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neoplastic or infectious etiologies of radiculopathy require prompt mechanism-specific treatment. With radiculopathy caused by disc herniation or foraminal stenosis, symptomatic treatment may be used to tide the patient over the acute period. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Management issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute lumbosacral radiculopathy and painful radicular symptoms, the following interventions may be useful:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest short-term treatment with either a nonsteroidal antiinflammatory drug (NSAID) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nonnarcotic analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest temporary activity modification, including avoidance of provocative activities (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Activity modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical or manual therapies are often tried for patients with persistent symptoms that are mild to moderate in nature, but there is no convincing evidence that they are effective for this indication. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of definitive data, use of opiates for acute back pain is a matter of clinical judgment. Such use is driven by patients with severe pain that is inadequately controlled with nonnarcotic analgesics. When prescribed, opioids should be used on a fixed schedule and only for a limited period of time. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Opioids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic or epidural glucocorticoids are options for patients with acute lumbosacral radiculopathy who have persistent severe radicular symptoms that are refractory to nonnarcotic analgesics and activity modification. However, with either systemic or epidural glucocorticoids, benefit &mdash; if any &mdash; is modest and transient. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Epidural glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with persistent disabling lumbar radicular symptoms who desire surgery and are good candidates, either open discectomy or microdiscectomy are reasonable options. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link&amp;anchor=H6#H6\">",
"       \"Subacute and chronic low back pain: Surgical treatment\", section on 'Lumbar disc prolapse'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/1\">",
"      Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine (Phila Pa 1976) 1993; 18:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/2\">",
"      Dreiser RL, Le Parc JM, V&eacute;licitat P, Lleu PL. Oral meloxicam is effective in acute sciatica: two randomised, double-blind trials versus placebo or diclofenac. Inflamm Res 2001; 50 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/3\">",
"      Goldie I. A clinical trial with indomethacin (indomee(R)) in low back pain and sciatica. Acta Orthop Scand 1968; 39:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/4\">",
"      Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008; :CD000396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/5\">",
"      Herrmann WA, Geertsen MS. Efficacy and safety of lornoxicam compared with placebo and diclofenac in acute sciatica/lumbo-sciatica: an analysis from a randomised, double-blind, multicentre, parallel-group study. Int J Clin Pract 2009; 63:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/6\">",
"      Pinto RZ, Maher CG, Ferreira ML, et al. Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. BMJ 2012; 344:e497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/7\">",
"      Vroomen PC, de Krom MC, Wilmink JT, et al. Lack of effectiveness of bed rest for sciatica. N Engl J Med 1999; 340:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/8\">",
"      Hofstee DJ, Gijtenbeek JM, Hoogland PH, et al. Westeinde sciatica trial: randomized controlled study of bed rest and physiotherapy for acute sciatica. J Neurosurg 2002; 96:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/9\">",
"      Hagen KB, Hilde G, Jamtvedt G, Winnem M. Bed rest for acute low-back pain and sciatica. Cochrane Database Syst Rev 2004; :CD001254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/10\">",
"      Chou R, Huffman LH, American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/11\">",
"      Finckh A, Zufferey P, Schurch MA, et al. Short-term efficacy of intravenous pulse glucocorticoids in acute discogenic sciatica. A randomized controlled trial. Spine (Phila Pa 1976) 2006; 31:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/12\">",
"      Haimovic IC, Beresford HR. Dexamethasone is not superior to placebo for treating lumbosacral radicular pain. Neurology 1986; 36:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/13\">",
"      Porsman O, Friis H. Prolapsed lumbar disc treated with intramuscularly administered dexamethasonephosphate. A prospectively planned, double-blind, controlled clinical trial in 52 patients. Scand J Rheumatol 1979; 8:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/14\">",
"      Hedeboe J, Buhl M, Ramsing P. Effects of using dexamethasone and placebo in the treatment of prolapsed lumbar disc. Acta Neurol Scand 1982; 65:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/15\">",
"      Friedman BW, Esses D, Solorzano C, et al. A randomized placebo-controlled trial of single-dose IM corticosteroid for radicular low back pain. Spine (Phila Pa 1976) 2008; 33:E624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/16\">",
"      Holve RL, Barkan H. Oral steroids in initial treatment of acute sciatica. J Am Board Fam Med 2008; 21:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/17\">",
"      Cuckler JM, Bernini PA, Wiesel SW, et al. The use of epidural steroids in the treatment of lumbar radicular pain. A prospective, randomized, double-blind study. J Bone Joint Surg Am 1985; 67:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/18\">",
"      Bush K, Hillier S. A controlled study of caudal epidural injections of triamcinolone plus procaine for the management of intractable sciatica. Spine (Phila Pa 1976) 1991; 16:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/19\">",
"      Carette S, Leclaire R, Marcoux S, et al. Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. N Engl J Med 1997; 336:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/20\">",
"      Karppinen J, Malmivaara A, Kurunlahti M, et al. Periradicular infiltration for sciatica: a randomized controlled trial. Spine (Phila Pa 1976) 2001; 26:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/21\">",
"      Armon C, Argoff CE, Samuels J, et al. Assessment: use of epidural steroid injections to treat radicular lumbosacral pain: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/22\">",
"      Pinto RZ, Maher CG, Ferreira ML, et al. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5655/abstract/23\">",
"      Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976) 2009; 34:1066.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5259 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5655=[""].join("\n");
var outline_f5_33_5655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMATIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonnarcotic analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Activity modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Epidural glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22776?source=related_link\">",
"      Lumbar spinal stenosis: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=related_link\">",
"      Patient information: Herniated disc (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/8/32898?source=related_link\">",
"      Patient information: Radiculopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=related_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_33_5656="ALA dehydratase porphyria";
var content_f5_33_5656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ALA dehydratase porphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5656/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5656/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5656/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5656/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/33/5656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delta-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    (ALA) dehydratase (ALAD) porphyria (ADP) is the rarest form of the inherited porphyrias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is one of the acute \"hepatic\" porphyrias, and is an autosomal recessive disorder resulting from a homozygous deficiency of ALAD, the second enzyme in the pathway of heme synthesis (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The incidence, pathophysiology, and diagnosis of ADP will be reviewed here. The treatment of ALAD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link&amp;anchor=H9#H9\">",
"     \"Porphyrias: An overview\", section on 'Environmental and metabolic influences'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALA dehydratase porphyria (ADP) is a rare homozygous autosomal recessive disease, with only five reported symptomatic cases: three German males, one Swedish baby boy, and one elderly Belgian man [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of genetic carriers for ALAD deficiency (ie, heterozygotes) in the normal population in Sweden is estimated to be approximately 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/5\">",
"     5",
"    </a>",
"    ]. Although subjects heterozygous for ALAD deficiency are asymptomatic, they may be considered to be at risk for developing ADP when exposed to environmental chemicals or toxins which further inhibit ALAD activity (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Potential public health issues'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENZYMOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALAD (ALA dehydratase; porphobilinogen synthase; EC 4.2.1.24) catalyzes the formation of the monopyrrole porphobilinogen (PBG) from two molecules of ALA (",
"    <a class=\"graphic graphic_figure graphicRef77451 \" href=\"UTD.htm?15/39/15997\">",
"     figure 2",
"    </a>",
"    ), the obligate precursor for porphyrins, heme, and other tetrapyrroles. In mammalian cells, ALAD is present in vast abundance. In the liver, for example, the activity of ALAD is 80 to 100-fold that of ALA synthase, the first and rate-limiting enzyme in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54358 \" href=\"UTD.htm?0/9/155\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/6\">",
"     6",
"    </a>",
"    ]. This normal abundance of ALAD explains why heterozygotes, who have approximately 50 percent of normal ALAD activity, are typically asymptomatic.",
"   </p>",
"   <p>",
"    The human enzyme is believed to be a homo-octamer with a subunit size of 36,274 daltons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/7\">",
"     7",
"    </a>",
"    ], and is encoded by the gene localized at chromosome 9q34 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/8\">",
"     8",
"    </a>",
"    ]. The enzyme requires an intact sulfhydryl group and one zinc atom (Zn2+) per subunit for full activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inhibition of enzymatic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to decreased activity due to an inherited genetic defect, ALAD can be inhibited under a number of circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over 80 percent of blood lead is bound to erythrocyte ALAD [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/10\">",
"       10",
"      </a>",
"      ]; lead inhibits ALAD activity by displacing zinc from the enzyme [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients with lead poisoning often develop neurologic symptoms, some of which resemble those seen in ADP [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/11\">",
"       11",
"      </a>",
"      ]. In addition, it has been reported that individuals with heterozygous ALAD deficiency and blood lead levels in the high normal range display evidence of subclinical lead poisoning, as manifest by a marked elevation of porphyrins in blood [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The most potent inhibitor of ALAD is succinylacetone [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/13\">",
"       13",
"      </a>",
"      ], a structural analogue of ALA, which is found in excess concentrations in the urine and blood of patients with hereditary tyrosinemia type 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/14\">",
"       14",
"      </a>",
"      ]. As a result, approximately 40 percent of children with hereditary tyrosinemia develop the signs and symptoms of ADP [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"       \"Disorders of tyrosine metabolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exposure to elemental iron [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/16\">",
"       16",
"      </a>",
"      ], lead [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/17\">",
"       17",
"      </a>",
"      ], trichloroethylene [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/18\">",
"       18",
"      </a>",
"      ], and styrene [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/19\">",
"       19",
"      </a>",
"      ] reduce ALAD activity in rats [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ALAD activity is moderately decreased in humans and rats with diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ALAD activity is reduced in patients undergoing dialysis for chronic renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/22\">",
"       22",
"      </a>",
"      ]. This is most likely due to zinc deficiency, as ALAD activity can be restored by the addition of zinc to the reaction mixture in vitro.",
"     </li>",
"     <li>",
"      ALAD activity is moderately reduced in smokers and in alcoholics, although the mechanism is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MOLECULAR GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the mouse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/24\">",
"     24",
"    </a>",
"    ] and the human [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/25\">",
"     25",
"    </a>",
"    ] ALAD genes contain two alternative noncoding exons, 1A and 1B, and 11 coding exons, 2 through 12.",
"   </p>",
"   <p>",
"    The housekeeping transcript, which includes exon 1A but not 1B, was identified in a human adult liver cDNA library, while an erythroid- specific transcript, which contains exon 1B but not 1A, was detected in a human K562 erythroleukemia cDNA library. The promoter region upstream of the housekeeping exon 1A is GC-rich and contains three potential Sp1 elements and a CCAAT box. Further upstream there are three potential GATA-1 binding sites and an AP1 site.",
"   </p>",
"   <p>",
"    The promoter region upstream of the erythroid-specific exon 1B has several CACCC boxes and two potential GATA-1 binding sites. These findings indicate that the human ALAD gene contains two promoter regions that generate housekeeping and erythroid-specific transcripts by alternate splicing, analogous to the expression of the human porphobilinogen deaminase (PBGD) gene.",
"   </p>",
"   <p>",
"    It is believed that the novel expression of housekeeping and erythroid-specific transcripts evolved to ensure sufficient heme biosynthesis for the high-level tissue specific production of hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Molecular pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first molecular analysis of the ALAD gene defect in ADP was made in German patient \"B\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/26\">",
"     26",
"    </a>",
"    ]. This patient had two separate point mutations of the ALAD gene, one in each allele. One was a base transition, G820 &mdash;&gt; A, termed \"G1\", resulting in an amino acid change, Ala274 &mdash;&gt; Thr in one allele, while the other was a base transition, C718 &mdash;&gt; T, termed \"G2\", which resulted in an amino acid change, Arg240 &mdash;&gt; Trp [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using the specific oligomer as the probe, it was determined that G1 was a paternal mutation, while G2 was a maternal mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/26\">",
"     26",
"    </a>",
"    ]. The G1 mutation occurred in the allele within the substrate-binding site, whereas the G2 mutation occurred downstream of this site. Phenotypic studies of the mutant enzymes, as examined by expression of the mutant cDNAs in CHO cells, demonstrated that the \"G1\" enzyme had little enzymatic activity, while the \"G2\" enzyme had a partial activity. In contrast, pulse-labeling studies demonstrated that the \"G1\" protein had a normal half-life, while the \"G2\" protein had a markedly decreased half-life.",
"   </p>",
"   <p>",
"    These findings indicate that the proband is a compound heterozygote for two different point mutations, accounting for the almost complete lack of enzymatic activity in his cells, and the half-normal activity in cells from his family members. In addition, these findings suggest that the protein product of the G1 allele, rather than that of the G2 allele, probably contributes to CRIM(+) in the proband, since the G2 product is more unstable than the G1 product. CRIM(+) refers to the presence of cross-reactive immunologic material, suggesting that the protein is present with reduced or no function. The fact that the patient survived may be due to the residual activity contributed by the G2 enzyme, since the G1 enzyme was essentially nonfunctional.",
"   </p>",
"   <p>",
"    In the second German male subject H, who also developed symptoms at the age of 15, there were two distinct molecular defects, each occurring in a separate allele. One was a G457 to A transition, resulting in V153M, while the other was a deletion of T818 and C819, resulting in a frame shift with a premature stop codon at amino acid position 294 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/28\">",
"     28",
"    </a>",
"    ]. Using ASO analysis, the former was shown to be inherited from his father, while the latter was from his mother. Expression of the former cDNA in CHO cells produced an ALAD protein with approximately 10 percent of normal activity, while the latter produced no protein. Thus, this patient was also heteroallelic for ALAD mutations.",
"   </p>",
"   <p>",
"    The third patient, a Swedish baby boy, presented with extremely severe acute hepatic porphyria symptoms starting at birth. This patient had another set of two distinct point mutations of the ALAD gene: a G823 to A base transition, resulting in V275M, and a G397 to A base transition, resulting in G133R [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/29\">",
"     29",
"    </a>",
"    ]. By using bacterial expression, both of these mutations were shown to encode an ALAD with little activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fourth patient was a Belgian male who was unique in that he developed ADP at the age of 63, at a time when he also developed polycythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/30\">",
"     30",
"    </a>",
"    ]. His erythrocyte ALAD activity was &lt;1 percent of normal, while his lymphocytes had &gt;20 percent ALAD activity. Sequence analysis of the ALAD cDNA in this subject revealed two base transitions in one allele, G177 to C, resulting in K59N, and G397 to A, resulting in G133R. The other allele was entirely normal. This finding indicates that the proband was heterozygous for ALAD deficiency. All family members of the proband who had decreased ALAD activity (approximately 50 percent of normal) were shown to have the same set of two base transitions. Expression of ALAD cDNAs in CHO cells revealed that K59N cDNA produced a protein with normal ALAD activity, while G133R and",
"    <span class=\"nowrap\">",
"     K59N/G133R",
"    </span>",
"    cDNAs produced proteins with 8 and 16 percent ALAD activity, respectively, compared with that expressed by wild type cDNA. Heterozygous ALAD deficiency, which should be clinically \"silent\", has nevertheless produced clinical ADP in this patient, presumably because there was expansion of the polycythemic clone in his erythroid cells, which carried only the mutant ALAD allele [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fifth patient was a 17-year-old German male who suffered from colicky abdominal pain and symptoms of severe polyneuropathy since two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/4\">",
"     4",
"    </a>",
"    ]. Erythrocyte ALAD activity was decreased to 8 percent of controls, and could not be activated by the addition of zinc or dithiothreitol. ALAD activity was about 50 percent in both parents, whereas the patient's brother had normal ALAD activity. Molecular genetic studies revealed two intronic mutations in the patient, namely an 11 C to A change and an 11 C to T change, both in intron 3. The former mutation was found in the mother, while the latter was present in the father.",
"   </p>",
"   <p>",
"    The healthy asymptomatic Swedish girl was found to have markedly decreased ALAD activity (12 percent of normal) by neonatal ALAD screening for hereditary tyrosinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/32\">",
"     32",
"    </a>",
"    ]. Molecular analysis of cloned ALAD cDNA revealed that this subject had a C36 to G base transition, and a T168 to C base transition in one allele, while the other allele was normal. The former transition resulted in a F12L amino acid substitution, while the latter was silent, representing polymorphism. F12L mutant cDNA produced a protein which underwent premature processing, resulting in practically no enzymatic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of this F12L mutant revealed that two of the eight ALAD subunits were excluded, while the remaining six subunits associated in a completely different manner, accounting for the near-total lack of enzymatic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/33\">",
"     33",
"    </a>",
"    ]. This finding also suggests that there must be a structural transition between octamer and hexamer, with two different dimeric structures in the subject.",
"   </p>",
"   <p>",
"    In contrast to these mutations, the K59N substitution in the ALAD allele has been found to be present in approximately 10 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/34\">",
"     34",
"    </a>",
"    ]. Consistent with the natural abundance of this variant, modeling of the K59N mutation indicates that it may not interfere with the proper folding or functioning of the human enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, the four other mutations found in the German and the Swedish patients' ADP are likely to have structural effects in the ALAD molecule, as judged by the yeast ALAD structure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ALAD protein was CRIM(+) in all four tested patients with ADP, suggesting that one or both alleles produced enzyme proteins with decreased catalytic activity. This hypothesis has been confirmed in one of the mutant protein products by expressing mutant cDNAs in CHO cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/27\">",
"     27",
"    </a>",
"    ]. The type of mutation in the ALAD gene is highly heterogeneous, with four distinct point mutations in two pedigrees, or five unique base transitions for six alleles. The data thus far suggest that the remaining two patients with ADP are likely to have a compound heterozygous mutation of the ALAD gene, since the mutation found in one allele has been confirmed to be absent in the other allele. Since CRIM(-) mutations are more common than CRIM(+) in other porphyrias, it is possible that, if and when more cases of ADP are discovered, some may demonstrate CRIM(-) mutation(s).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Animal model for ADP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A whiteout mutant of the medaka, Oryzias latipes, exhibited hypochromic anemia due to a missense mutation in the gene for ALAD, representing a possible animal model for human ALA dehydratase porphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADP excrete a large amount of ALA, but not porphobilinogen (PBG), into the urine (",
"    <a class=\"graphic graphic_table graphicRef50908 \" href=\"UTD.htm?23/20/23885\">",
"     table 2",
"    </a>",
"    ). In addition to the deficiency of ALAD, the acute hepatic porphyria syndrome in these patients is believed to be exacerbated by an overexpression of ALA synthase, due to a loss of heme-mediated repression (",
"    <a class=\"graphic graphic_figure graphicRef63700 \" href=\"UTD.htm?21/49/22301\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Theoretically, patients with ADP should be more sensitive to drugs, hormones, and chemicals which either increase ALA synthase through induction of cytochrome P450, or reduce the concentration of heme via inhibition of heme oxygenase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link&amp;anchor=H4#H4\">",
"     \"Porphyrias: An overview\", section on 'Regulation of heme synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, subjects heterozygous for ALAD deficiency have a partial deficiency of ALAD (approximately 50 percent of normal activity) and no clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Case summaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;All five reported patients with ADP were unrelated, including three adolescent males of German origin. Their symptomatology varied widely, ranging from a severe tumultuous porphyric syndrome in a Swedish child to an essentially asymptomatic Belgian patient who suddenly developed ADP porphyria at 63 years of age.",
"   </p>",
"   <p>",
"    Two German patients developed sudden abdominal cramps, with nausea, constipation, and vomiting at age 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/39\">",
"     39",
"    </a>",
"    ]. Because of the \"strong abdominal pain\", one patient underwent appendectomy. A distal motor neuron polyneuropathy, muscular hypertonicity, tachycardia, and loss of appetite also occurred, with extensor paralysis during acute attacks. Urinary excretion of ALA, but not PBG, was markedly elevated (",
"    <a class=\"graphic graphic_table graphicRef50908 \" href=\"UTD.htm?23/20/23885\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ALAD activity in red cells and lymphocytes of the patient and the",
"    <span class=\"nowrap\">",
"     parents/siblings",
"    </span>",
"    were &lt;1 and approximately 50 percent of normal, respectively (",
"    <a class=\"graphic graphic_table graphicRef50908 \" href=\"UTD.htm?23/20/23885\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Both patients were CRIM(+), amounting to 20 percent and 33 percent of control levels of ALAD, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/41\">",
"     41",
"    </a>",
"    ]. This finding suggests that the molecular defect in these patients may be due, at least in part, to the expression of a nonfunctional enzyme subunit from a mutant allele [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical syndrome of acute hepatic porphyria in the Swedish patient, a baby boy, was unique in that severe symptoms were present at birth. This is highly unusual for any acute hepatic porphyria, which commonly becomes symptomatic at or after the time of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/6\">",
"     6",
"    </a>",
"    ]. At the age of 3, he had recurrent attacks of pain, vomiting, hyponatremia, and polyneuropathy involving respiratory muscle motor function. The patient excreted large amounts of ALA and coproporphyrin in the urine, but only moderately elevated amounts of PBG (approximately five times the upper limit of normal) (",
"    <a class=\"graphic graphic_table graphicRef50908 \" href=\"UTD.htm?23/20/23885\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Erythrocyte ALAD activity was less than 5 percent of normal in this patient, and between 26 and 51 percent in both parents, both grandfathers, and a sibling. Attempts to treat the porphyria syndrome with infusions of glucose, hematin, or blood were unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/29\">",
"     29",
"    </a>",
"    ]. At the age of 6, the patient underwent liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/42\">",
"     42",
"    </a>",
"    ]. While the postoperative period was complicated by episodes of severe paralysis and respiratory failure requiring respirator support, the patient's condition gradually improved, and one year after transplantation, the patient was without pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fourth patient was a 63-year-old Belgian male [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/30\">",
"     30",
"    </a>",
"    ]. At the age of 63, he suddenly developed a myeloproliferative disease along with porphyric neuropathy including a gradually worsening loss of strength in both arms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/43\">",
"     43",
"    </a>",
"    ]. The patient showed markedly elevated plasma ALA concentration (89",
"    <span class=\"nowrap\">",
"     &micro;g/dL;",
"    </span>",
"    normal &lt;10",
"    <span class=\"nowrap\">",
"     &micro;g/dL),",
"    </span>",
"    while plasma PBG was undetectable. Urinary ALA concentration (105",
"    <span class=\"nowrap\">",
"     mg/L;",
"    </span>",
"    normal &lt;5",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    was also abnormally elevated, without an increase in PBG concentration. The erythrocyte ALAD activity of the patient was &lt;1 percent of normal (",
"    <a class=\"graphic graphic_table graphicRef50908 \" href=\"UTD.htm?23/20/23885\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of myeloproliferative disease with ADP in the proband is particularly noteworthy. The close temporal relationship between the onset of ADP and thrombocytosis, and between the relapses of his porphyria and the myeloproliferative disorder following treatment with radiophosphorus, strongly favor a causal relationship between the myeloproliferative disease and the disturbances in porphyrin metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proband's erythrocytes had less than 1 percent ALAD activity, while his EBV-exposed lymphoblastoid cells had approximately 20 percent enzyme activity. The myeloproliferative disorder is known to accompany a clonal expansion of his erythropoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/44-46\">",
"     44-46",
"    </a>",
"    ], which does not influence lymphoid lineages. This picture is consistent with his being heterozygous for a mutant ALAD allele at birth, as shown as clonal expansion of the mutant allele in erythroid cells, but not in lymphoid cells. Thus, a heterozygous ALAD deficiency, which usually has no clinical phenotype, was induced to develop the clinical porphyria via clonal expansion of cells expressing only the abnormal phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fifth patient was a 17-year-old German male who suffered from colicky abdominal pain and symptoms of severe polyneuropathy since two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/4\">",
"     4",
"    </a>",
"    ]. Urinary ALA was increased 33-fold, and coproporphyrin III 79-fold at the time of diagnosis. PBG and uroporphyrin were only marginally elevated, while there was no increase in fecal porphyrins. In his erythrocytes, Zn-protoporphyrin was elevated fivefold, and ALAD activity was decreased to 8 percent of controls, and could not be activated by the addition of zinc or dithiothreitol. Lead levels were normal. ALAD activity was about 50 percent in both parents, whereas the patient's brother had normal ALAD activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Potential public health issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although heterozygotes with single ALAD mutations do not usually display clinical consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/32,38\">",
"     32,38",
"    </a>",
"    ], they represent a population which could be at risk if exposed to toxic chemicals that reduce ALAD activity (eg, iron, lead, trichloroethylene, succinyl acetone, styrene oxide) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. As an example, individuals with heterozygous ALAD deficiency and blood lead levels in the high normal range may display evidence of subclinical lead poisoning, as manifest by marked elevation of porphyrins in blood. Thus, the implications of heterozygosity for ALAD deficiency may bear significantly on the susceptibility of affected individuals to toxic effects of environmental chemicals that interact with this enzyme.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADP is characterized by markedly increased production of ALA, such that ALA production is 10 to 20 times that of PBG. Acute intermittent porphyria (AIP), on the other hand, is characterized by increased production of both ALA and PBG, often to a comparable (ie, 1:1) extent. The fact that AIP and ADP are clinically indistinguishable suggests that ALA or its metabolites, rather than PBG, may be the neurotoxic agent. This point is further supported by the finding that patients with hereditary tyrosinemia frequently develop ADP along with its neurologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/47\">",
"     47",
"    </a>",
"    ], most likely via the marked inhibition of ALAD by succinylacetone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/13,48\">",
"     13,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADP can be differentiated from AIP and the other acute hepatic porphyrias by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inheritance is autosomal recessive, rather than autosomal dominant",
"     </li>",
"     <li>",
"      Production of PBG is not increased, since ALAD is required for PBG synthesis (",
"      <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ALAD activity is markedly reduced, usually to &lt;5 percent of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, when neurovisceral symptoms suggestive of a hepatic porphyria are present, urinary ALA, PBG, and porphyrin concentrations should be determined in an aliquot from a 24 hour urine collection. In ADP, excretion of ALA is markedly increased, while excretion of PBG is normal to only slightly increased. The diagnosis is confirmed by showing markedly reduced ALAD activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Aminolevulinic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal excretion of ALA is less than 7 mg per 24 hours; in an attack of ADP, urinary ALA excretion is markedly elevated, with typical values being 3 to 10 or more times the upper limit of normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Porphobilinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal excretion of PBG is less than 2 mg per 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5656/abstract/49\">",
"     49",
"    </a>",
"    ]. In ADP, normal to only slightly increased excretion of PBG is seen (",
"    <a class=\"graphic graphic_table graphicRef50908 \" href=\"UTD.htm?23/20/23885\">",
"     table 2",
"    </a>",
"    ). The increase in excretion of PBG in ADP is always significantly",
"    <strong>",
"     less",
"    </strong>",
"    than that of ALA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Urinary and fecal porphyrin analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary and erythrocyte porphyrins may be elevated in ADP in a nonspecific pattern (",
"    <a class=\"graphic graphic_table graphicRef50908 \" href=\"UTD.htm?23/20/23885\">",
"     table 2",
"    </a>",
"    ). Fecal porphyrin excretion is generally within the normal range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Assay for ALAD activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;If ADP is suspected, erythrocyte or lymphocyte ALAD activity should be determined. Activity should be less than 5 percent of normal in the patient and approximately 50 percent in both parents.",
"   </p>",
"   <p>",
"    If testing is not available locally, all of the above assays can be obtained through the SmithKline Beecham Clinical Laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ADP includes the other porphyrias and toxic states in which ALAD activity is suppressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other porphyrias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ADP suffer from neurovisceral complaints and do not demonstrate photosensitivity. Therefore, the differential diagnosis includes the other \"hepatic\" porphyrias, which are acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria. Unlike ADP, the latter three porphyrias are associated with increased excretion of",
"    <strong>",
"     both",
"    </strong>",
"    ALA and PBG, often in equimolar amounts, and have normal values for ALAD activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Inhibition of ALAD activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions in which ALAD activity can be inhibited include lead poisoning, hereditary tyrosinemia, zinc deficiency, alcoholism, smoking, diabetes mellitus, and chronic renal insufficiency (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Inhibition of enzymatic activity'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ADP, as with the other hepatic porphyrias, is two-fold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute attacks are treated by withdrawal of the offending agent (if any), infusion of glucose, and, if the patient is still symptomatic, intravenous infusion of heme preparations or administration of inhibitors of heme oxygenase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of acute intermittent porphyria\", section on 'Treatment of the acute attack'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Future attacks are prevented by avoiding agents known to stimulate ALA synthase activity and by avoiding those agents known to inhibit ALAD activity (see above). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of acute intermittent porphyria\", section on 'Prevention of future attacks'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25675488\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delta",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    dehydratase porphyria (ALA dehydratase porphyria, ADP) is the least common of the acute porphyrias. It is an autosomal recessive disorder resulting from a homozygous deficiency of ALA dehydratase (ALAD), the second enzyme in the pathway of heme synthesis (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25675527\">",
"    <span class=\"h2\">",
"     When to suspect ADP",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALAD porphyria is suspected in any patient with acute neurovisceral complaints (eg, recurrent attacks of pain, vomiting, hyponatremia, polyneuropathy). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25675557\">",
"    <span class=\"h2\">",
"     How to confirm the diagnosis of ADP",
"    </span>",
"    &nbsp;&mdash;&nbsp;When neurovisceral symptoms suggestive of a hepatic porphyria are present, urinary ALA, PBG, and porphyrin concentrations should be determined in an aliquot from a 24-hour urine collection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ADP, excretion of ALA is markedly increased, while excretion of PBG is normal to only slightly increased. This distinguishes ADP from the other acute &ldquo;hepatic&rdquo; porphyrias, which all demonstrate increased excretion of PBG in the urine. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is confirmed by showing markedly reduced ALAD activity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Assay for ALAD activity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25675680\">",
"    <span class=\"h2\">",
"     Treatment and prevention of acute attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ADP, as with the other hepatic porphyrias, is two-fold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute attacks are treated by withdrawal of the offending agent (if any), infusion of glucose, and, if the patient is still symptomatic, intravenous infusion of heme preparations or administration of inhibitors of heme oxygenase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of acute intermittent porphyria\", section on 'Treatment of the acute attack'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Future attacks are prevented by avoiding agents known to stimulate ALA synthase activity and by avoiding those agents known to inhibit ALAD activity (see above). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of acute intermittent porphyria\", section on 'Prevention of future attacks'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/1\">",
"      Sassa S. ALAD porphyria. Semin Liver Dis 1998; 18:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/2\">",
"      Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood 2012; 120:4496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/3\">",
"      Maruno M, Furuyama K, Akagi R, et al. Highly heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria. Blood 2001; 97:2972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/4\">",
"      Doss MO, Stauch T, Gross U, et al. The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis 2004; 27:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/5\">",
"      Thunell S, Holmberg L, Lundgren J. Aminolaevulinate dehydratase porphyria in infancy. A clinical and biochemical study. J Clin Chem Clin Biochem 1987; 25:5.",
"     </a>",
"    </li>",
"    <li>",
"     Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Metabolic and Molecular Bases of Inherited Disease, 7th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 1995. Vol 2, p.2103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/7\">",
"      Wetmur JG, Bishop DF, Ostasiewicz L, Desnick RJ. Molecular cloning of a cDNA for human delta-aminolevulinate dehydratase. Gene 1986; 43:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/8\">",
"      Potluri VR, Astrin KH, Wetmur JG, et al. Human delta-aminolevulinate dehydratase: chromosomal localization to 9q34 by in situ hybridization. Hum Genet 1987; 76:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/9\">",
"      Sassa S. Delta-aminolevulinic acid dehydratase assay. Enzyme 1982; 28:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/10\">",
"      Bergdahl IA, Grubb A, Sch&uuml;tz A, et al. Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol 1997; 81:153.",
"     </a>",
"    </li>",
"    <li>",
"     Granick JL, Sassa S, Kappas A. Some biochemical and clinical aspects of lead intoxication. In: Advances in clinical chemistry, Bodansky O, Latner AL (Eds), Academic Press, New York 1978. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/12\">",
"      Doss M, Laubenthal F, Stoeppler M. Lead poisoning in inherited delta-aminolevulinic acid dehydratase deficiency. Int Arch Occup Environ Health 1984; 54:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/13\">",
"      Sassa S, Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 1983; 71:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/14\">",
"      Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A 1977; 74:4641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/15\">",
"      Rank JM, Pascual-Leone A, Payne W, et al. Hematin therapy for the neurologic crisis of tyrosinemia. J Pediatr 1991; 118:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/16\">",
"      Bonkovsky HL, Healey JF, Lincoln B, et al. Hepatic heme synthesis in a new model of experimental hemochromatosis: studies in rats fed finely divided elemental iron. Hepatology 1987; 7:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/17\">",
"      Sassa S, Granick S, Kappas A. Effect of lead and genetic factors on heme biosynthesis in the human red cell. Ann N Y Acad Sci 1975; 244:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/18\">",
"      Fujita H, Koizumi A, Yamamoto M, et al. Inhibition of delta-aminolevulinate dehydratase in trichloroethylene-exposed rats, and the effects on heme regulation. Biochim Biophys Acta 1984; 800:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/19\">",
"      Fujita H, Koizumi A, Hayashi N, Ikeda M. Reduced synthesis of 5-aminolevulinate dehydratase in styrene-treated rats. Biochim Biophys Acta 1986; 867:89.",
"     </a>",
"    </li>",
"    <li>",
"     Sassa S, Fujita H, Kappas A. Genetic and chemical influences on heme biosynthesis. In: Highlights of modern biochemistry, Kotyk A, Skoda J, Paces V, et al. (Eds), Utrecht: VSP International Science Publishers, 1989. p.329.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/21\">",
"      Fern&aacute;ndez-Cuartero B, Rebollar JL, Batlle A, Enriquez de Salamanca R. Delta aminolevulinate dehydratase (ALA-D) activity in human and experimental diabetes mellitus. Int J Biochem Cell Biol 1999; 31:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/22\">",
"      Guolo M, Stella AM, Melito V, et al. Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Int J Biochem Cell Biol 1996; 28:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/23\">",
"      McColl KE, Moore MR, Thompson GG, Goldberg A. Abnormal haem biosynthesis in chronic alcoholics. Eur J Clin Invest 1981; 11:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/24\">",
"      Bishop TR, Miller MW, Beall J, et al. Genetic regulation of delta-aminolevulinate dehydratase during erythropoiesis. Nucleic Acids Res 1996; 24:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/25\">",
"      Kaya AH, Plewinska M, Wong DM, et al. Human delta-aminolevulinate dehydratase (ALAD) gene: structure and alternative splicing of the erythroid and housekeeping mRNAs. Genomics 1994; 19:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/26\">",
"      Ishida N, Fujita H, Noguchi T, et al. Message amplification phenotyping of an inherited delta-aminolevulinate dehydratase deficiency in a family with acute hepatic porphyria. Biochem Biophys Res Commun 1990; 172:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/27\">",
"      Ishida N, Fujita H, Fukuda Y, et al. Cloning and expression of the defective genes from a patient with delta-aminolevulinate dehydratase porphyria. J Clin Invest 1992; 89:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/28\">",
"      Akagi R, Shimizu R, Furuyama K, et al. Novel molecular defects of the delta-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria. Hepatology 2000; 31:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/29\">",
"      Plewinska M, Thunell S, Holmberg L, et al. delta-Aminolevulinate dehydratase deficient porphyria: identification of the molecular lesions in a severely affected homozygote. Am J Hum Genet 1991; 49:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/30\">",
"      Hassoun A, Verstraeten L, Mercelis R, Martin JJ. Biochemical diagnosis of an hereditary aminolaevulinate dehydratase deficiency in a 63-year-old man. J Clin Chem Clin Biochem 1989; 27:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/31\">",
"      Akagi R, Nishitani C, Harigae H, et al. Molecular analysis of delta-aminolevulinate dehydratase deficiency in a patient with an unusual late-onset porphyria. Blood 2000; 96:3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/32\">",
"      Akagi R, Yasui Y, Harper P, Sassa S. A novel mutation of delta-aminolaevulinate dehydratase in a healthy child with 12% erythrocyte enzyme activity. Br J Haematol 1999; 106:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/33\">",
"      Breinig S, Kervinen J, Stith L, et al. Control of tetrapyrrole biosynthesis by alternate quaternary forms of porphobilinogen synthase. Nat Struct Biol 2003; 10:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/34\">",
"      Wetmur JG. Influence of the common human delta-aminolevulinate dehydratase polymorphism on lead body burden. Environ Health Perspect 1994; 102 Suppl 3:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/35\">",
"      Erskine PT, Senior N, Awan S, et al. X-ray structure of 5-aminolaevulinate dehydratase, a hybrid aldolase. Nat Struct Biol 1997; 4:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/36\">",
"      Sakamoto D, Kudo H, Inohaya K, et al. A mutation in the gene for delta-aminolevulinic acid dehydratase (ALAD) causes hypochromic anemia in the medaka, Oryzias latipes. Mech Dev 2004; 121:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/37\">",
"      Granick S, Sinclair P, Sassa S, Grieninger G. Effects by heme, insulin, and serum albumin on heme and protein synthesis in chick embryo liver cells cultured in a chemically defined medium, and a spectrofluorometric assay for porphyrin composition. J Biol Chem 1975; 250:9215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/38\">",
"      Bird TD, Hamernyik P, Nutter JY, Labbe RF. Inherited deficiency of delta-aminolevulinic acid dehydratase. Am J Hum Genet 1979; 31:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/39\">",
"      Doss M, von Tiepermann R, Schneider J, Schmid H. New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr 1979; 57:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/40\">",
"      Sassa S, Fujita H, Doss M, et al. Hereditary hepatic porphyria due to homozygous delta-aminolevulinic acid dehydratase deficiency: studies in lymphocytes and erythrocytes. Eur J Clin Invest 1991; 21:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/41\">",
"      de Verneuil H, Doss M, Brusco N, et al. Hereditary hepatic porphyria with delta aminolevulinate dehydrase deficiency: immunologic characterization of the non-catalytic enzyme. Hum Genet 1985; 69:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/42\">",
"      Thunell S, Henrichson A, Floderus Y, et al. Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem 1992; 30:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/43\">",
"      Mercelis R, Hassoun A, Verstraeten L, et al. Porphyric neuropathy and hereditary delta-aminolevulinic acid dehydratase deficiency in an adult. J Neurol Sci 1990; 95:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/44\">",
"      Prchal JT, Throckmorton DW, Carroll AJ 3rd, et al. A common progenitor for human myeloid and lymphoid cells. Nature 1978; 274:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/45\">",
"      Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/46\">",
"      Abkowitz JL, Fialkow PJ, Niebrugge DJ, et al. Pancytopenia as a clonal disorder of a multipotent hematopoietic stem cell. J Clin Invest 1984; 73:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/47\">",
"      Mitchell G, Larochelle J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990; 322:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/48\">",
"      Tschudy DP, Hess RA, Frykholm BC. Inhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid. J Biol Chem 1981; 256:9915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5656/abstract/49\">",
"      Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7095 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5656=[""].join("\n");
var outline_f5_33_5656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25675488\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENZYMOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inhibition of enzymatic activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MOLECULAR GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Molecular pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Animal model for ADP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Case summaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Potential public health issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Aminolevulinic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Porphobilinogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Urinary and fecal porphyrin analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Assay for ALAD activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other porphyrias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Inhibition of ALAD activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25675488\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25675527\">",
"      When to suspect ADP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25675557\">",
"      How to confirm the diagnosis of ADP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25675680\">",
"      Treatment and prevention of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7095\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7095|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/39/15997\" title=\"figure 2\">",
"      Formation of porphobilinogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/49/22301\" title=\"figure 3\">",
"      ALA dehydratase porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7095|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/9/155\" title=\"table 1\">",
"      Heme pathway enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/20/23885\" title=\"table 2\">",
"      ALAD porphyria lab findings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=related_link\">",
"      Management of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_33_5657="Progesterone supplementation to reduce the risk of spontaneous preterm birth";
var content_f5_33_5657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5657/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5657/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5657/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5657/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5657/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/33/5657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14419317\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm birth (delivery prior to 37 weeks or 259 days of gestation) complicates 1 in 8 deliveries in the United States, but accounts for over 85 percent of all perinatal morbidity and mortality. Efforts to delay delivery in women presenting with acute preterm labor have been largely unsuccessful. For this reason, much attention has focused on preventative strategies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"       \"Cervical insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"       \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419324\">",
"    <span class=\"h1\">",
"     ROLE OF PROGESTERONE IN PREGNANCY MAINTENANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone is a steroid hormone initially produced by the corpus luteum. It is critical for the maintenance of early pregnancy until the placenta takes over this function at 7 to 9 weeks of gestation, and its name is derived from this function: pro-gestational steroidal ketone. Indeed, removal of the source of progesterone (the corpus luteum) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/1\">",
"     1",
"    </a>",
"    ] or administration of a progesterone receptor antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/2\">",
"     2",
"    </a>",
"    ] readily induces abortion before 7 weeks (49 days) of gestation.",
"   </p>",
"   <p>",
"    The role of progesterone later in pregnancy, however, is less clear. Progesterone appears be important in maintaining uterine quiescence in the latter half of pregnancy, possibly by limiting the production of stimulatory prostaglandins and inhibiting the expression of contraction-associated protein genes within the myometrium, including ion channels, oxytocin and prostaglandin receptors, and gap junctions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Although levels of progesterone in the maternal circulation do not change significantly in the weeks preceding labor, the onset of labor both at term and preterm is associated with a functional withdrawal of progesterone activity at the level of the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/3-10\">",
"     3-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progesterone has been shown to prevent apoptosis in fetal membrane explants, under both basal and pro-inflammatory conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/11\">",
"     11",
"    </a>",
"    ]. This may help to prevent preterm premature rupture of membranes (PPROM), which is a common cause of preterm birth.",
"   </p>",
"   <p>",
"    These observations provide the rationale for use of progesterone supplementation to prevent preterm labor and birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419338\">",
"    <span class=\"h1\">",
"     EFFICACY OF PROGESTERONE FOR PREVENTION OF PRETERM BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of progesterone supplementation for prevention of preterm birth depends primarily on appropriate patient selection (",
"    <a class=\"graphic graphic_table graphicRef66456 \" href=\"UTD.htm?34/6/34924\">",
"     table 1",
"    </a>",
"    ). In addition, there is evidence from in vitro and animal research that the type of progestin, formulation, dose, and route of delivery have a significant impact on efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These factors likely played a role in the discordant findings reported in the trials discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22816883\">",
"    <span class=\"h2\">",
"     Pregnancies likely to benefit from progesterone supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good evidence that progesterone supplementation reduces the rate of spontaneous singleton preterm birth in women who have had a previous spontaneous preterm singleton birth and in women with a short cervix on ultrasound examination in the current pregnancy. Among women with prior preterm birth and a singleton pregnancy, progesterone treatment decreases the risk of preterm birth by one-third (OR 0.66, 95% CI 0.53-0.82; four randomized trials), corresponding to an absolute reduction in risk of preterm birth between 0 and 26 percent across studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk of neonatal death is halved (OR 0.52, 95% CI 0.25-0.96). Among women with short cervical length, progesterone treatment leads to an absolute reduction in risk of preterm birth between 8.8 and 15.2 percent. This evidence has been reviewed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/14\">",
"     14",
"    </a>",
"    ] and is summarized below. Management of these pregnancies is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"       \"Cervical insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"       \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419345\">",
"    <span class=\"h3\">",
"     Spontaneous singleton preterm birth in prior pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of randomized trials have concluded that progesterone supplementation is protective against recurrent preterm birth and improves neonatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/14-21\">",
"     14-21",
"    </a>",
"    ]. As an example, in one meta-analysis, the benefits of progesterone supplementation compared to placebo were [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Birth &lt;37 weeks (RR 0.77, 95% CI 0.67-0.87)",
"     </li>",
"     <li>",
"      Birth &lt;35 weeks (RR 0.77, 95% CI 0.63-0.96)",
"     </li>",
"     <li>",
"      Birth &lt;32 weeks (RR 0.61, 95% CI 0.45-0.82)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Perinatal/neonatal",
"      </span>",
"      death (RR 0.54, 95% CI 0.31-0.93)",
"     </li>",
"     <li>",
"      Respiratory distress (RR 0.75, 95% CI 0.57-97)",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis (RR 0.30, 95% CI 0.10-0.93)",
"     </li>",
"     <li>",
"      The reduction in intraventricular hemorrhage was not statistically significant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following two trials were the seminal trials showing the benefit of progesterone supplementation for prevention of recurrent preterm birth:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal Fetal Medicine Units Network trial &mdash; Meis and co-investigators randomly assigned 459 women with a documented history of spontaneous singleton preterm delivery &lt;37 completed weeks to weekly intramuscular injections of 17-alpha-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=see_link\">",
"       hydroxyprogesterone caproate",
"      </a>",
"      (17P) (250 mg) or placebo beginning at 16 to 20 weeks of gestation and continuing until 36 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/22\">",
"       22",
"      </a>",
"      ]. Active prophylaxis significantly reduced the risk of delivery at all gestational ages studied:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &lt;37 weeks (36 versus 55 percent in the placebo group [RR, 0.66; 95% CI, 0.54-0.81]),",
"     </li>",
"     <li>",
"      &lt;35 weeks (21 versus 31 percent [RR, 0.67; 95% CI, 0.48-0.93])",
"     </li>",
"     <li>",
"      &lt;32 weeks (11 versus 20 percent [RR, 0.58; 95% CI, 0.37-0.91])",
"      <br/>",
"      <br/>",
"      Progesterone exposed infants had less perinatal morbidity, with significantly reduced rates of necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen. There was no evidence of virilization of female offspring, which is a theoretic concern of this therapy.",
"      <br/>",
"      <br/>",
"      Secondary analysis of these data found that women with a history of a prior spontaneous preterm birth &lt;34 completed weeks were most likely to benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brazilian trial &mdash; da Fonseca and co-investigators randomly assigned 142 women at high-risk for preterm delivery (based on at least one previous spontaneous singleton preterm birth, prophylactic cervical cerclage, or uterine malformation) to daily supplementation with progesterone vaginal suppositories (100 mg) or placebo from 24 through 34 weeks of gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/24\">",
"       24",
"      </a>",
"      ]. Active prophylaxis significantly reduced the risk of delivery at all gestational ages studied:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &lt;37 weeks (14 versus 29 percent in the placebo group)",
"     </li>",
"     <li>",
"      &lt;34 weeks (3 versus 19 percent in the placebo group)",
"      <br/>",
"      <br/>",
"      By monitoring all patients with an external tocodynamometer once a week for 60 minutes, the investigators were also able to demonstrate a significant difference in the frequency of spontaneous uterine contractions between the two groups, suggesting that progesterone supplementation may exert its effect by maintaining uterine quiescence in the latter half of pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the largest randomized trial of progesterone supplementation for the prevention of recurrent preterm birth did not find a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/25\">",
"     25",
"    </a>",
"    ]. In this trial, 659 women with a history of a prior spontaneous preterm birth were randomly assigned to self-administer progesterone gel (90 mg) or placebo vaginally each day from between 18 to 23 weeks and 37 weeks of gestation. Rates of recurrent preterm birth in this cohort were high, approximately 25 percent prior to 35 weeks and 40 percent prior to 37 weeks of gestation. Progesterone supplementation did not significantly reduce the frequency of preterm birth at any gestational age compared with placebo, and there were no differences among the groups for any maternal or neonatal outcome measure. The reason for the discrepancy between this and other trials is unclear, but may have to do with the type, dose, and route of administration of progesterone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although supplemental progesterone appears to be effective in preventing preterm birth in some high-risk women, it should not be seen as a panacea. An analysis of 2002 national birth certificate data demonstrated that, even if all eligible women had received progesterone prophylaxis, it would only have reduced the overall preterm birth rate in the United States by approximately 2 percent (from 12.1 to 11.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/26\">",
"     26",
"    </a>",
"    ]. This is because only 22.5 percent of preterm births in 2002 were recurrent and prophylaxis reduces the incidence of recurrent preterm birth by only about 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Long-term benefits and other effects of progesterone supplementation are not yet clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419366\">",
"    <span class=\"h3\">",
"     Short cervix in current pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical shortening is a known risk factor for preterm birth in both low- and high-risk populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .) Data from randomized trials show that vaginal progesterone supplementation prolongs pregnancy in women with a sonographically-detected short cervix, and may be as effective as cerclage. Whether progesterone acts by attenuating further cervical shortening is not yet clear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of progesterone supplementation in women with asymptomatic midtrimester sonographic short cervix are best illustrated by a meta-analysis of individual patient data from five placebo-controlled randomized trials (n = 775 pregnancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with vaginal progesterone was associated with significant reductions in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Preterm birth &lt;28, &lt;33, and &lt;35 weeks (RR 0.50, 0.58, and 0.69, respectively)",
"     </li>",
"     <li>",
"      Respiratory distress syndrome (RR 0.48, 95% CI 0.30-0.76)",
"     </li>",
"     <li>",
"      Composite neonatal morbidity and mortality (RR 0.57, 95% CI 0.40-0.81)",
"     </li>",
"     <li>",
"      Birthweight &lt;1500 g (RR 0.55, 95% CI 0.38-0.80)",
"     </li>",
"     <li>",
"      Neonatal intensive care unit admission (RR 0.75, 95% CI 0.59-0.94)",
"     </li>",
"     <li>",
"      Need for mechanical ventilation (RR 0.66, 95% CI 0.44-0.98)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These benefits were similar at progesterone doses of 90, 100, and 200 mg daily",
"     </li>",
"     <li>",
"      Women with and without a history of prior preterm birth derived similar benefits",
"     </li>",
"     <li>",
"      Beneficial effects were noted at cervical lengths &lt;10 mm, 10 to 20 mm, and 21 to 25 mm, but only the 10 to 20 mm group reached statistical significance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent trial in which nulliparous women with a singleton gestation between 16 and",
"    <span class=\"nowrap\">",
"     22",
"     <sup>",
"      3/7",
"     </sup>",
"    </span>",
"    weeks and cervical length &lt;30 mm were randomly assigned to weekly intramuscular 17P (250 mg) or placebo through 36 weeks, treatment with 17P did not reduce the risk of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/30\">",
"     30",
"    </a>",
"    ]. These findings, which are in contrast to those of the meta-analysis, may have been related to the type of progesterone (intramuscular 17P instead of vaginal progesterone), the inclusion of women with cervical length up to 29 mm, or both. In addition to chance, methodologic issues may have played a role; for example, the study was stopped before completion because of lack of efficacy at the scheduled interim analysis.",
"   </p>",
"   <p>",
"    Placement of a pessary has also been reported to be useful for reducing the risk of preterm birth in women with a short cervix. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link&amp;anchor=H7012170#H7012170\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\", section on 'Singleton, no prior preterm birth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419373\">",
"    <span class=\"h2\">",
"     Pregnancies where the benefit of progesterone supplementation is unclear",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited high-quality evidence regarding progesterone supplementation in women at high risk of preterm birth, but without a short cervix or a prior history of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419380\">",
"    <span class=\"h3\">",
"     Positive fetal fibronectin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a positive cervicovaginal fetal fibronectin test is a risk factor for preterm birth, there is no information on use of progesterone supplementation in such women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31324600\">",
"    <span class=\"h3\">",
"     Cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with a prior preterm birth, continuing 17P supplementation after placement of a cerclage has not been proven to be useful, but available data are limited to secondary analysis of one underpowered trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link&amp;anchor=H25211294#H25211294\">",
"     \"Cervical insufficiency\", section on 'Women with prior pregnancy losses or preterm births'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419387\">",
"    <span class=\"h3\">",
"     Preterm premature rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone supplementation is not beneficial in women with PPROM in the current pregnancy. A placebo-controlled, randomized trial in women with PPROM at 20 to 30 weeks of gestation found no evidence that weekly injection of 17P extended the latent period before delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, women with a history of preterm birth due to PPROM appear to benefit from progesterone supplementation in subsequent pregnancies; these women were included in the prior randomized trials of the efficacy of progesterone supplementation in women with prior preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. As discussed above (see",
"    <a class=\"local\" href=\"#H14419324\">",
"     'Role of progesterone in pregnancy maintenance'",
"    </a>",
"    above), progesterone appears to prevent apoptosis in fetal membranes in vitro under both basal and pro-inflammatory conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/11\">",
"     11",
"    </a>",
"    ], thereby providing a mechanism by which progesterone supplementation may prevent recurrent PPROM and preterm birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419401\">",
"    <span class=\"h3\">",
"     Acute preterm labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies have given progesterone in the setting of acute preterm labor.",
"   </p>",
"   <p>",
"    The use of progesterone in women who remain undelivered after an episode of acute preterm labor is investigational and most providers (including the author) do not routinely recommend progesterone supplementation in this setting.",
"   </p>",
"   <p>",
"    Four randomized trials evaluating progesterone supplementation in this setting have been performed and have generally not shown a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/27,33-35\">",
"     27,33-35",
"    </a>",
"    ]. In three of the four trials, progesterone maintenance therapy after successful parenteral tocolysis did not significantly reduce the rate of preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The largest of these trials was a multicenter trial (n = 188) in which women with singleton pregnancies at 24 to 31 weeks, cervical length less than 25 mm, and preterm labor successfully arrested by tocolytic treatment were randomized to receive no 17P or 500 mg of intramuscular 17P semiweekly until 36 weeks or preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/35\">",
"     35",
"    </a>",
"    ]. Administration of 17P did not significantly increase the time to delivery or reduce preterm birth &lt;32, 34, or 37 weeks. However, some smaller trials have reported a benefit. One trial (n = 60) observed a significant reduction in preterm delivery (OR 0.15; 95% CI, 0.04-0.58) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/27\">",
"     27",
"    </a>",
"    ] and another trial (n = 70) reported a significantly longer latency to delivery interval (36.1&plusmn;17.9 days versus 24.5&plusmn;27.2 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/33\">",
"     33",
"    </a>",
"    ]. These differences may have been due to chance or to differences in study design.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4918763\">",
"    <span class=\"h3\">",
"     Spontaneous twin preterm birth in prior pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prior preterm birth is a risk factor for a subsequent preterm birth whether the initial preterm delivery was a singleton or a twin pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. No study has specifically evaluated whether progesterone supplementation decreases the risk of a preterm birth of a singleton after a previous preterm birth of twins, but a benefit is plausible given the existing data and epidemiologic studies described above. We suggest 17P supplementation for women with a singleton pregnancy who have had a prior preterm birth, singleton or twin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419408\">",
"    <span class=\"h3\">",
"     Multiple gestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is now consistent evidence from several clinical trials that routine progesterone supplementation does not prolong gestation or improve perinatal outcome in women with multiple gestations (preterm birth &lt;35 weeks: OR 1.18, 95% CI 0.79-1.39) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/14\">",
"     14",
"    </a>",
"    ]. The observation that progesterone supplementation does not prevent preterm birth in multiple pregnancy suggests that the mechanism leading to preterm labor and delivery in multiples, such as excessive uterine stretch, is different from that in singletons. This argument is supported by a study showing that progesterone does not inhibit stretch-induced Mitogen activated protein kinase (MAPK) activation or gene expression in myometrial cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31324701\">",
"    <span class=\"h4\">",
"     Twin pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of seven trials of preterm birth rates in women with twin gestations managed with or without progesterone supplementation reported progesterone treatment did not result in a significant reduction in preterm birth (&lt;28 weeks: RR 1.24, 95% CI 0.85&ndash;1.82; &lt;32 weeks: RR 1.16, 95% CI 0.89&ndash;1.51, &lt;34 weeks: RR 1.10, 95% CI 0.77&ndash;1.58) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/20\">",
"     20",
"    </a>",
"    ]. Progesterone administration was associated with increased rates of perinatal death (RR 1.55, 95% CI 1.01&ndash;2.37), respiratory distress syndrome (RR 1.22, 95% CI 1.04&ndash;1.45), and composite adverse outcome",
"    <em>",
"    </em>",
"    (RR 1.21, 95% CI 1.03&ndash;1.43), which could not be explained and was not observed in triplet pregnancies. A subsequent randomized trial evaluated the efficacy of high dose vaginal progesterone (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and found it no more effective in preventing preterm birth than lower dose therapy (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or a placebo, suggesting that inadequate dosing is not the reason for lack of efficacy in twin gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimum management of a woman with a prior singleton preterm birth who now has a twin pregnancy with normal cervical length is unclear. A prior preterm birth of a singleton is an independent and additive risk factor for preterm birth of twins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/42\">",
"     42",
"    </a>",
"    ]. In the absence of data clearly showing harm or lack of efficacy in this specific setting, the author prescribes 17P to women with twin pregnancies who have had a previous unexplained spontaneous preterm birth. However, this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In twin pregnancies with a short cervix, however, a meta-analysis of individual patient data described above (see",
"    <a class=\"local\" href=\"#H14419366\">",
"     'Short cervix in current pregnancy'",
"    </a>",
"    above) found that treatment with vaginal progesterone was associated with a nonsignificant reduction in preterm birth &lt;33 weeks of gestation (30.4 versus 44.8 percent; RR 0.70, 95% CI 0.34-1.44) and a significant reduction in composite neonatal morbidity and mortality (23.9 versus 39.7 percent; RR 0.52, 95% CI 0.29-0.93) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/29\">",
"     29",
"    </a>",
"    ]. Based on these data, we treat twin pregnancies with a short cervix with vaginal progesterone. In a randomized trial, twice weekly injections of 500 mg 17P did not result in a reduction in preterm birth (&lt;37, &lt;34, or &lt;32 weeks) or neonatal",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    in women with twin pregnancy and a short cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31324776\">",
"    <span class=\"h4\">",
"     Triplet pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of two placebo-controlled randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] of 17P supplementation of asymptomatic women with triplet pregnancies also reported no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/20\">",
"     20",
"    </a>",
"    ]. Supplementation did not result in a statistical reduction in preterm birth &lt;28 weeks or &lt;32 weeks, neonatal death, respiratory distress syndrome, grade 3-4 intraventricular hemorrhage, necrotizing enterocolitis, sepsis, or composite adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4573841\">",
"    <span class=\"h2\">",
"     Uterine anomaly or ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on the effectiveness of progesterone therapy for prevention of preterm birth in women with uterine malformations or who conceive with assisted reproductive technology (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450693\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor side effects are related to the route of administration, and include injection site reactions and vaginal irritation or discharge.",
"   </p>",
"   <p>",
"    The only potential adverse effect that has been reported is a three-fold increase in risk of developing gestational diabetes in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], but this finding was not confirmed in analysis of data from another large study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22816692\">",
"    <span class=\"h1\">",
"     PROGESTERONE PREPARATIONS, ROUTES, AND DOSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most randomized trials have not directly compared routes of administration or doses; all formulations have been effective at reducing the risk of preterm birth compared with no",
"    <span class=\"nowrap\">",
"     treatment/placebo",
"    </span>",
"    (meta estimates: intramuscular 17P OR 0.75, 95% CI 0.60 0.90, vaginal 17P OR 0.76, 95% CI 0.57-0.98, oral 17P OR 0.56, 95% CI 0.36-0.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/14\">",
"     14",
"    </a>",
"    ]. However, one small randomized trial that compared vaginal with intramuscular progesterone in women with a previous preterm midtrimester birth noted fewer deliveries &lt;34 weeks with the vaginal route (OR 0.58, 95% CI 0.37-0.89;",
"    <span class=\"nowrap\">",
"     42/253",
"    </span>",
"    [16.6 percent] versus",
"    <span class=\"nowrap\">",
"     64/249",
"    </span>",
"    [25.7 percent], p&lt;0.02); none of the women had a short cervix at the start of the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/50\">",
"     50",
"    </a>",
"    ]. More and larger comparative trials need to be done to determine whether one route of administration is superior to another.",
"   </p>",
"   <p>",
"    Evidence is insufficient to define the optimum gestational age for starting treatment. Further study in humans is important since, as discussed above, there is evidence from in vitro and animal research that the type of progestin, formulation, dose, and route of delivery have a significant impact on efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31325196\">",
"    <span class=\"h2\">",
"     17-alpha-hydroxyprogesterone (17P)",
"    </span>",
"    &nbsp;&mdash;&nbsp;17-alpha-hydroxyprogesterone (17P) is a natural progesterone metabolite made by the corpus luteum and placenta with minimal to no androgenic activity. It is typically administered intramuscularly. Doses have ranged from 25 mg every five days to 1000 mg weekly, beginning as early as 16 weeks of gestation. We use a 250 mg dose. Standard contraindications to progesterone administration include hormone-sensitive cancer, liver disease, or uncontrolled hypertension.",
"   </p>",
"   <p>",
"    In February 2011, the United States Food and Drug Administration (FDA) approved the use of progesterone supplementation (specifically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=see_link\">",
"     hydroxyprogesterone caproate",
"    </a>",
"    injections [Makena&trade;; KV Pharmaceutical Co, St Louis, MO]) to reduce the risk of recurrent preterm birth in women with a singleton pregnancy who have a history of a prior spontaneous preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/51\">",
"     51",
"    </a>",
"    ]. This is the first time that the FDA has approved a medication for the prevention of preterm birth, and represents the first approval of a drug specifically for use in pregnancy in more than 15 years. A version of the active ingredient of Makena (hydroxyprogesterone caproate) is available to patients whose physicians request the drug from a pharmacist who compounds it. In June 2012, the FDA performed an independent review of 55 samples of compounded hydroxyprogesterone caproate products and did not identify any major safety problems. However, they did state that, &ldquo;&hellip; (FDA) approved drug products, such as Makena, provide a greater assurance of safety and effectiveness than do compounded products&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of 17P in pregnancy has been confirmed by numerous epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/53-56\">",
"     53-56",
"    </a>",
"    ] and clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ]. Several studies have reported a nonstatistical increase in risk of miscarriage and stillbirth in pregnancies exposed to progestins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/22,32,57,58\">",
"     22,32,57,58",
"    </a>",
"    ], but others could not confirm this observation or observed a nonstatistical decrease in these risks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/45,59,60\">",
"     45,59,60",
"    </a>",
"    ]. This association requires further study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/61\">",
"     61",
"    </a>",
"    ]. For example, a logistic regression analysis demonstrated significant treatment-genotype interactions, which could result in either a beneficial or harmful treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another concern is a possible increase in risk of hypospadias in male offspring exposed to exogenous progestins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]; even if confirmed, this risk is limited to exposure prior to 11 weeks of gestation and thus is not relevant to women with prior preterm delivery, as they will receive the drug after 16 weeks of gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31325203\">",
"    <span class=\"h2\">",
"     Vaginal progesterone preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural progesterone is typically administered vaginally. The advantage of vaginal progesterone is its high uterine bioavailability since uterine exposure occurs before the first pass through the liver. It also has few systemic side effects, but vaginal irritation can be bothersome and the drug needs to be administered daily. Doses of 90 to 400 mg have been effective, beginning as early as 18 weeks of gestation. We use 100 mg administered vaginally each evening; however, in some areas a 200 mg suppository may be more readily available and less costly. &nbsp;",
"   </p>",
"   <p>",
"    A vaginal suppository&nbsp;can be&nbsp;prepared by a compounding pharmacy utilizing a commercially available standardized kit. A pharmacist kit for compounding Progesterone Vaginal Suppository, USP, is available from:",
"    <a class=\"external\" href=\"file://www.cutispharma.com/proinst.html\">",
"     file://www.cutispharma.com/proinst.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Other options include a 100 mg micronized progesterone vaginal tablet or an 8 percent vaginal gel containing 90 mg micronized progesterone per dose.&nbsp;Both preparations are commercially available in the United States, but not approved for prevention of preterm birth in cervical shortening. The FDA concluded the data in the manufacturer&rsquo;s application did not sufficiently support the efficacy of progesterone 8 percent gel compared with placebo in reducing the risk of preterm births before 33 completed weeks of gestation among women with a short cervical length, but the drug was safe in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4573887\">",
"    <span class=\"h2\">",
"     Oral progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;An oral micronized preparation of natural progesterone also exists. Daily doses of 900 to 1600 mg have been given. Reported side effects include sleepiness, fatigue and headache [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5657/abstract/25,66\">",
"     25,66",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14419429\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progesterone supplementation reduces the risk of preterm birth by about one-third in women with a singleton pregnancy who have had a previous spontaneous singleton preterm birth and in women with a short cervix on ultrasound examination in the current pregnancy. (See",
"      <a class=\"local\" href=\"#H22816883\">",
"       'Pregnancies likely to benefit from progesterone supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a singleton pregnancy who have had a previous spontaneous singleton preterm birth, we suggest progesterone treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest intramuscular injections of 17-alpha-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=see_link\">",
"       hydroxyprogesterone caproate",
"      </a>",
"      rather than vaginal progesterone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), beginning in the second trimester (16 to 20 weeks) and continuing through the 36",
"      <sup>",
"       th",
"      </sup>",
"      week of gestation. We prescribe 250 mg weekly. (See",
"      <a class=\"local\" href=\"#H14419345\">",
"       'Spontaneous singleton preterm birth in prior pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We manage women with a singleton pregnancy who have had a prior spontaneous twin birth the same way. (See",
"    <a class=\"local\" href=\"#H4918763\">",
"     'Spontaneous twin preterm birth in prior pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with midtrimester cervical shortening (defined as &le;20 mm before 24 weeks) and no prior spontaneous singleton preterm birth, we suggest vaginal progesterone treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) through the 36",
"      <sup>",
"       th",
"      </sup>",
"      week of gestation. Reasonable options include a vaginal suppository (100 or 200 mg), gel (90 mg), or tablet (100 mg micronized progesterone). (See",
"      <a class=\"local\" href=\"#H14419366\">",
"       'Short cervix in current pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine progesterone supplementation does not appear to be useful for preventing preterm birth in multiple gestations. (See",
"      <a class=\"local\" href=\"#H14419408\">",
"       'Multiple gestations'",
"      </a>",
"      above.). However:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with twin pregnancies and a previous spontaneous preterm birth, the author prescribes 17-alpha-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=see_link\">",
"       hydroxyprogesterone caproate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For women with twin pregnancies and a short cervix in the current pregnancy, the author prescribes vaginal progesterone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine progesterone supplementation does not appear to be useful for preventing preterm birth in the setting of preterm premature rupture of membranes or after an episode of arrested preterm labor. There is no information on efficacy in women with a positive fetal fibronectin test. The effect in women with a cerclage is unclear (See",
"      <a class=\"local\" href=\"#H14419387\">",
"       'Preterm premature rupture of membranes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14419380\">",
"       'Positive fetal fibronectin test'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31324600\">",
"       'Cerclage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14419401\">",
"       'Acute preterm labor'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/1\">",
"      Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet Gynecol Surv 1978; 33:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/2\">",
"      Peyron R, Aub&eacute;ny E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993; 328:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/3\">",
"      Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med 1999; 341:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/4\">",
"      Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000; 21:514.",
"     </a>",
"    </li>",
"    <li>",
"     Norwitz ER, Lye SJ. Biology of parturition. In: Creasy RK, Resnick R, Iams JD, et al, eds. Creasy &amp; Resnick&rsquo;s Maternal-Fetal Medicine, 6th ed. Philadelphia: Elsevier; 2009:69-85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/6\">",
"      Condon JC, Jeyasuria P, Faust JM, et al. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proc Natl Acad Sci U S A 2003; 100:9518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/7\">",
"      Oh SY, Kim CJ, Park I, et al. Progesterone receptor isoform (A/B) ratio of human fetal membranes increases during term parturition. Am J Obstet Gynecol 2005; 193:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/8\">",
"      Renthal NE, Chen CC, Williams KC, et al. miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor. Proc Natl Acad Sci U S A 2010; 107:20828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/9\">",
"      Mesiano S, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reprod Sci 2011; 18:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/10\">",
"      Lockwood CJ, Stocco C, Murk W, et al. Human labor is associated with reduced decidual cell expression of progesterone, but not glucocorticoid, receptors. J Clin Endocrinol Metab 2010; 95:2271.",
"     </a>",
"    </li>",
"    <li>",
"     Luo G, Abrahams VM, Tadesse S, Funai EF, Hodgson EJ, Gao J, Norwitz ER. Progesterone inhibits basal and TNF���-induced apoptosis in fetal membranes: A novel mechanism to explain progesterone-mediated prevention of preterm birth. Reprod. Sci 2010; 17:532.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/12\">",
"      Kuon RJ, Shi SQ, Maul H, et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol 2010; 202:455.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/13\">",
"      O'Sullivan MD, Hehir MP, O'Brien YM, Morrison JJ. 17 alpha-hydroxyprogesterone caproate vehicle, castor oil, enhances the contractile effect of oxytocin in human myometrium in pregnancy. Am J Obstet Gynecol 2010; 202:453.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Likis FE, Andrews JC, Woodworth AL, et al. Progestogens for Prevention of Preterm Birth. Comparative Effectiveness Review No. 74. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I). AHRQ Publication No. 12-EHC105-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/15\">",
"      Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 2005; 105:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/16\">",
"      Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 2006; 194:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/17\">",
"      Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol 2008; 112:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/18\">",
"      Rode L, Langhoff-Roos J, Andersson C, et al. Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies. Acta Obstet Gynecol Scand 2009; 88:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/19\">",
"      Coomarasamy A, Thangaratinam S, Gee H, Khan KS. Progesterone for the prevention of preterm birth: a critical evaluation of evidence. Eur J Obstet Gynecol Reprod Biol 2006; 129:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/20\">",
"      Sotiriadis A, Papatheodorou S, Makrydimas G. Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis. Ultrasound Obstet Gynecol 2012; 40:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/21\">",
"      Likis FE, Edwards DR, Andrews JC, et al. Progestogens for preterm birth prevention: a systematic review and meta-analysis. Obstet Gynecol 2012; 120:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/22\">",
"      Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/23\">",
"      Spong CY, Meis PJ, Thom EA, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol 2005; 193:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/24\">",
"      da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/25\">",
"      O'Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/26\">",
"      Petrini JR, Callaghan WM, Klebanoff M, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005; 105:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/27\">",
"      Facchinetti F, Paganelli S, Comitini G, et al. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196:453.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/28\">",
"      Durnwald CP, Lynch CD, Walker H, Iams JD. The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time. Am J Obstet Gynecol 2009; 201:410.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/29\">",
"      Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012; 206:124.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/30\">",
"      Grobman WA, Thom EA, Spong CY, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol 2012; 207:390.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/31\">",
"      Meis PJ, Society for Maternal-Fetal Medicine. 17 hydroxyprogesterone for the prevention of preterm delivery. Obstet Gynecol 2005; 105:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/32\">",
"      Briery CM, Veillon EW, Klauser CK, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 2011; 204:54.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/33\">",
"      Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008; 48:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/34\">",
"      Noblot G, Audra P, Dargent D, et al. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991; 40:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/35\">",
"      Rozenberg P, Chauveaud A, Deruelle P, et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol 2012; 206:206.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/36\">",
"      Schaaf JM, Hof MH, Mol BW, et al. Recurrence risk of preterm birth in subsequent twin pregnancy after preterm singleton delivery. BJOG 2012; 119:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/37\">",
"      Rafael TJ, Hoffman MK, Leiby BE, Berghella V. Gestational age of previous twin preterm birth as a predictor for subsequent singleton preterm birth. Am J Obstet Gynecol 2012; 206:156.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/38\">",
"      Schaaf JM, Hof MH, Mol BW, et al. Recurrence risk of preterm birth in subsequent singleton pregnancy after preterm twin delivery. Am J Obstet Gynecol 2012; 207:279.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/39\">",
"      Facco FL, Nash K, Grobman WA. Are women who have had a preterm twin delivery at greater risk of preterm birth in a subsequent singleton pregnancy? Am J Obstet Gynecol 2007; 197:253.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/40\">",
"      Lei K, Chen L, Cryar BJ, et al. Uterine stretch and progesterone action. J Clin Endocrinol Metab 2011; 96:E1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/41\">",
"      Serra V, Perales A, Meseguer J, et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG 2013; 120:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/42\">",
"      Ananth CV, Kirby RS, Vintzileos AM. Recurrence of preterm birth in twin pregnancies in the presence of a prior singleton preterm birth. J Matern Fetal Neonatal Med 2008; 21:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/43\">",
"      Durnwald CP. 17 OHPC for prevention of preterm birth in twins: back to the drawing board? Am J Obstet Gynecol 2013; 208:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/44\">",
"      Senat MV, Porcher R, Winer N, et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Am J Obstet Gynecol 2013; 208:194.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/45\">",
"      Caritis SN, Rouse DJ, Peaceman AM, et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009; 113:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/46\">",
"      Combs CA, Garite T, Maurel K, et al. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2010; 203:248.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/47\">",
"      Waters TP, Schultz BA, Mercer BM, Catalano PM. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy. Obstet Gynecol 2009; 114:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/48\">",
"      Rebarber A, Istwan NB, Russo-Stieglitz K, et al. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007; 30:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/49\">",
"      Gyamfi C, Horton AL, Momirova V, et al. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am J Obstet Gynecol 2009; 201:392.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/50\">",
"      Maher MA, Abdelaziz A, Ellaithy M, Bazeed MF. Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone. Acta Obstet Gynecol Scand 2013; 92:215.",
"     </a>",
"    </li>",
"    <li>",
"     Statement on Makena [press release]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; March 30, 2011. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm249025.htm (accessed on May 9, 2011).",
"    </li>",
"    <li>",
"     Updated FDA Statement on Compounded Versions of hydroxyprogesterone caproate (the active ingredient in Makena) www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308546.htm (Accessed on June 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/53\">",
"      Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 1980; 22:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/54\">",
"      Resseguie LJ, Hick JF, Bruen JA, et al. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974. Fertil Steril 1985; 43:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/55\">",
"      Raman-Wilms L, Tseng AL, Wighardt S, et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995; 85:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/56\">",
"      Northen AT, Norman GS, Anderson K, et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007; 110:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/57\">",
"      Rouse DJ, Caritis SN, Peaceman AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007; 357:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/58\">",
"      Norman JE, Mackenzie F, Owen P, et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 2009; 373:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/59\">",
"      Combs CA, Garite T, Maurel K, et al. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2011; 204:221.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/60\">",
"      Berghella V, Figueroa D, Szychowski JM, et al. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010; 202:351.e1.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration, Center for Drug Evaluation and Research. Summary minutes of the Advisory Committee for Reproductive Health Drugs, August 29, 2006. file://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4227M1.pdf (accessed June 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/62\">",
"      Manuck TA, Lai Y, Meis PJ, et al. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2011; 205:135.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/63\">",
"      Silver RI, Rodriguez R, Chang TS, Gearhart JP. In vitro fertilization is associated with an increased risk of hypospadias. J Urol 1999; 161:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/64\">",
"      Carmichael SL, Shaw GM, Laurent C, et al. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med 2005; 159:957.",
"     </a>",
"    </li>",
"    <li>",
"     Background Document for Meeting of Advisory Committee for Reproductive Health Drugs. January 20, 2012. NDA 22-139. Progesterone gel (8%) file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM287987.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5657/abstract/66\">",
"      Thornton JG. Progesterone and preterm labor--still no definite answers. N Engl J Med 2007; 357:499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16560 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5657=[""].join("\n");
var outline_f5_33_5657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14419429\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14419317\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14419324\">",
"      ROLE OF PROGESTERONE IN PREGNANCY MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14419338\">",
"      EFFICACY OF PROGESTERONE FOR PREVENTION OF PRETERM BIRTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22816883\">",
"      Pregnancies likely to benefit from progesterone supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14419345\">",
"      - Spontaneous singleton preterm birth in prior pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14419366\">",
"      - Short cervix in current pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14419373\">",
"      Pregnancies where the benefit of progesterone supplementation is unclear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14419380\">",
"      - Positive fetal fibronectin test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31324600\">",
"      - Cerclage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14419387\">",
"      - Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14419401\">",
"      - Acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4918763\">",
"      - Spontaneous twin preterm birth in prior pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14419408\">",
"      - Multiple gestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H31324701\">",
"      Twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H31324776\">",
"      Triplet pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4573841\">",
"      Uterine anomaly or ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450693\">",
"      SIDE EFFECTS AND ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22816692\">",
"      PROGESTERONE PREPARATIONS, ROUTES, AND DOSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31325196\">",
"      17-alpha-hydroxyprogesterone (17P)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31325203\">",
"      Vaginal progesterone preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4573887\">",
"      Oral progesterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14419429\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/16560\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16560|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/6/34924\" title=\"table 1\">",
"      Progesterone supplementation to prevent preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_33_5658="Giant cell tumor of bone";
var content_f5_33_5658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Giant cell tumor of bone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5658/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5658/contributors\">",
"     David M Thomas, FRACP, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5658/contributors\">",
"     Jayesh Desai, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5658/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5658/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/33/5658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/33/5658/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/33/5658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell tumor of bone (GCTB) is a relatively rare, benign but locally aggressive osteolytic skeletal neoplasm of young adults. First recognized in 1818 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/1\">",
"     1",
"    </a>",
"    ], it was not until 1940 that GCTB was formally distinguished from other tumors of bone, such as aneurysmal bone cyst, chondroblastoma, and nonossifying fibroma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although regarded as a benign tumor, GCTB represents a continuum of neoplasia, and clinical behavior is not predictable based upon clinical, radiographic, or histologic features. GCTB can be locally aggressive, and it has a propensity to recur locally after curettage alone. Furthermore, in about 2 to 3 percent of cases, distant metastases occur, most often to the lungs. However, pulmonary metastases do not carry the same connotation as metastases associated with malignant tumors, such as lung cancer or sarcoma. In most cases, clinical behavior is benign, and metastatic disease does not lead to the death of the patient, hence the designation \"benign pulmonary implants\". Rarely, GCTB undergoes true malignant transformation.",
"   </p>",
"   <p>",
"    Historically, there has been a lack of prospective, randomized clinical trials to guide clinical management of GCTB, partly owing to the rarity of these tumors and to their primarily surgical treatment. Retrospective data from large single-institution series has provided some degree of consensus as to optimal local management. More recently, improved understanding of the molecular and cellular biology of GCTB has led to the identification of new targeted therapies for the disease. The most promising of these is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , a fully humanized monoclonal antibody directed against the osteoclast differentiation factor RANKL (Receptor Activator of Nuclear factor Kappa B (NF-kB) Ligand), a molecule that appears to be critical to the pathogenesis of GCTB.",
"   </p>",
"   <p>",
"    This topic review will discuss the epidemiology, clinical and imaging features, staging, pathology and molecular pathogenesis, and treatment approaches for GCTB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, GCTB accounts for approximately 3 to 5 percent of all primary bone tumors and 15 to 20 percent of all benign bone tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asian populations have a significantly higher incidence than do Western populations. In China, GCTB represents approximately 20 percent of all primary bone tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GCTB occurs predominantly after skeletal maturity, with a peak incidence in the 20s and 30s, and there is a slight female predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/3,7,8\">",
"     3,7,8",
"    </a>",
"    ]. The disease is extremely rare before the age of 20. Patients who develop a GCTB before epiphyseal closure tend to have a higher incidence of vertebral primary tumors and multicentricity as compared to those who develop the lesion after skeletal maturity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, this has not been seen in all series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an increased incidence of giant cell tumors in patients with Paget disease of bone. They typically occur in the skull or pelvic bones of patients who have longstanding polyostotic disease and also can arise in nonosseous tissues (extraskeletal osteoclastoma). There are reports of familial clustering of both Paget disease and GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"    </a>",
"    .) Interestingly, a rare congenital, sporadic syndrome closely resembling Noonan syndrome is associated with predisposition to giant-cell rich lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of short stature\", section on 'Noonan syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentation of a GCTB is pain, swelling, and limitation of joint movement at the primary site. The most commonly affected sites are the epiphyses of the long bones (",
"    <a class=\"graphic graphic_figure graphicRef76662 \" href=\"UTD.htm?22/53/23391\">",
"     figure 1",
"    </a>",
"    ); approximately one-half of all cases affect the distal femur or proximal tibia. Less commonly involved sites include the vertebra, pelvis, sacrum, and the skull and craniofacial bones. Patients with tumors in the axial skeleton may present with neurologic signs and symptoms.",
"   </p>",
"   <p>",
"    In approximately 10 to 35 percent of patients, thinning of the bone cortex in weight-bearing regions can result in a pathologic fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The articular surface may be involved.",
"   </p>",
"   <p>",
"    Most cases are solitary; multicentric GCTB accounts for less than 1 percent of total reported cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/9\">",
"     9",
"    </a>",
"    ]. As noted above, patients with multicentric disease tend to be younger than those with a solitary GCTB. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In rare circumstances, patients may present with metastatic disease, mostly in lung. However, in general, lung metastases are most common in the setting of locally recurrent disease (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Natural history'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Imaging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern imaging techniques to determine the extent of disease involvement incorporate a combination of anatomic (x-ray, computed tomography [CT], magnetic resonance imaging [MRI]) and functional (bone scan, positron emission tomography [PET]) scans. On plain x-rays, GCTB typically appears as an expansile eccentrically-placed lytic area, which is the result of intratumoral hemorrhage. The lesion normally involves the epiphysis and the adjacent metaphysis (",
"    <a class=\"graphic graphic_figure graphicRef50795 \" href=\"UTD.htm?13/34/13864\">",
"     figure 2",
"    </a>",
"    ), and there is frequent extension to the subchondral plate, sometimes with joint involvement. Matrix calcification and reactive periosteal new bone formation are typically absent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to plain radiographs, CT scans give a more accurate assessment of cortical thinning and penetration, and the presence or absence of bone mineralization. Primary bone formation within the tumor suggests the presence of a primary osteosarcoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI is particularly useful for assessing the integrity of the surrounding soft tissue, including neurovascular structures, and the extent of subchondral extension into adjacent joints. The characteristic findings on MRI are an expansile hypervascular mass with cystic changes and heterogeneous low to intermediate signal intensity on T1-weighted images and intermediate to high intensity on T2-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Large amounts of hemosiderin are often present, accounting for areas of low signal intensity in both T1 and T2-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the radiographic findings, the differential diagnosis may include a lytic metastasis (particularly an expansile highly vascular metastasis from renal cell or thyroid carcinoma), a primary bone tumor, a brown tumor of hyperparathyroidism, an aneurysmal bone cyst, or nonossifying fibroma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Osteitis fibrosa cystica'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest CT may be indicated to evaluate for the presence of pulmonary metastases. Given that metastatic spread is most common in the setting of a local recurrence, we routinely order a chest CT only in patients who have locally recurrent disease.",
"   </p>",
"   <p>",
"    Radionuclide bone scan may be helpful in staging multicentric disease. Changes on bone scan, typically decreased uptake of radiotracer in the center of the tumor, are not specific for GCTB. Aneurysmal bone cysts have a similar appearance. As with chest CT, there is no consensus as to the indications for obtaining a bone scan.",
"   </p>",
"   <p>",
"    There are limited data regarding the utility of fluorine-18 fluorodeoxyglucose (18F-FDG)-PET for newly diagnosed GCTB. Unlike many benign bone tumors, GCTB accumulate the FDG tracer, presumably because the osteoclast-like giant cells are intensely metabolically active [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, whether there are any advantages to evaluation with FDG PET as compared to conventional imaging with CT, MRI, and bone scan is unclear.",
"   </p>",
"   <p>",
"    Changes in FDG uptake over time correlate with tumor metabolism and angiogenic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/23\">",
"     23",
"    </a>",
"    ]. In our experience, FDG-PET is a highly sensitive biomarker of response to targeted therapeutics. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'RANKL inhibitors: Denosumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different classifications of GCTB based upon histology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/2\">",
"     2",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     clinical/radiographic",
"    </span>",
"    appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] have been proposed. As an example, the Campanacci grading system stratifies patients according to clinical and radiographic appearance as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I - Intraosseous lesions with well-marginated borders and an intact cortex",
"     </li>",
"     <li>",
"      Grade II - More extensive intraosseous lesions having a thin cortex without loss of cortical continuity",
"     </li>",
"     <li>",
"      Grade III - Extraosseous lesions that break through the cortex and extend into soft tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, classification systems such as these are of limited clinical utility. They do not correlate well with histologic appearance, and provide little prognostic information regarding the risk of local recurrence or metastatic behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the generally benign nature of most GCTBs, the spectrum of disease behavior is highly variable and unpredictable. There are varying degrees of local aggressiveness, and focal symptoms typically result from bony destruction, cortical breakthrough, and expansion into soft tissues. Disease within the axial skeleton, which is often unresectable, can cause severe and debilitating local complications.",
"   </p>",
"   <p>",
"    Some cases behave in a malignant fashion. However, the term \"malignant\" GCTB includes multiple entities and therefore can be confusing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In about 2 to 3 percent of cases, metastases develop, most often in the setting of locally recurrent disease, and most frequently to the lungs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/10\">",
"       10",
"      </a>",
"      ]. However, in general, pulmonary metastases from a GCTB do not carry the same connotation as do metastases from other solid tumors such as sarcoma. For most patients, the clinical outcomes remain consistent with the generally benign character of the tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/24\">",
"       24",
"      </a>",
"      ], hence their designation as \"benign\" pulmonary implants [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/8,18\">",
"       8,18",
"      </a>",
"      ]. However, in a small number of cases, pulmonary metastases (particularly if accompanied by metastases in other sites [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/25\">",
"       25",
"      </a>",
"      ]) contribute to death [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/10,26\">",
"       10,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an extremely small number of cases, true spontaneous malignant transformation of GCTB is reported [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/27-31\">",
"       27-31",
"      </a>",
"      ]. The term \"malignancy in giant cell tumor\" is used by the World Health Organization (WHO) to designate a high-grade sarcoma arising in a GCTB (primary) or at the site of a previously documented GCTB (secondary) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some cases of secondary malignancy represent a radiation-induced sarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/33\">",
"       33",
"      </a>",
"      ]. When a primary malignant GCTB is discovered, it may represent a primary bone sarcoma with prominent areas of hemorrhage and giant cell reaction that was missed at initial diagnosis rather than malignant transformation of a GCTB [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/34\">",
"       34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      When true malignant transformation does occur within a GCTB, the prognosis is worse than for a benign GCTB, yet somewhat better than for other high-grade sarcomas. Five-year survival rates in two series of 28 and 26 cases of malignant GCTB, were 50 and 82 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/27,30\">",
"       27,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HISTOLOGY, HISTOGENESIS, AND MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grossly, GCTB is a fleshy, reddish tumor often containing cystic and hemorrhagic areas. The tumor may breach the cortex and extend into soft tissues, and there is little or no periosteal reaction.",
"   </p>",
"   <p>",
"    Microscopically, the tumor is composed of sheets of round to oval polygonal or elongated mononuclear cells which are interspersed with uniformly distributed large osteoclast giant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/18\">",
"     18",
"    </a>",
"    ]. When the tumor is present in the lung, the histologic features are identical to the primary tumor, including the presence of giant cells.",
"   </p>",
"   <p>",
"    The prominent multinucleated cells, which may exceed 50 percent of the total cell content of the tumor, are thought to derive from circulating monocytes which have converted into osteoclasts in the osseous environment. This conclusion is supported by light, ultrastructural, and immunological marker studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/35-39\">",
"     35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is generally accepted that the characteristic large osteoclastic giant cells are not neoplastic. The mononuclear cells, which represent the neoplastic component, are thought to arise from primitive mesenchymal stromal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/40\">",
"     40",
"    </a>",
"    ]. These cells have characteristics of osteoblast progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] and express RANKL (Receptor Activator of Nuclear factor Kappa B (NF-kB) Ligand), a growth factor that is essential for the recruitment of osteoclasts by osteoblasts and their maturation under normal physiologic conditions. The role of RANKL in the molecular pathogenesis of GCTB is discussed further below.",
"   </p>",
"   <p>",
"    Histologic grading does not appear to be of value in predicting either locally aggressive behavior or the development of metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/18\">",
"     18",
"    </a>",
"    ]. The stromal cells show no cytologic features suggestive of malignancy, unless associated with malignant transformation (which is rare, (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Natural history'",
"    </a>",
"    above)).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of GCT includes other giant cell-rich tumors, including aneurysmal bone cyst, fibrous metaphyseal defects, giant cell rich osteosarcoma, chondroblastoma, and brown tumor associated with hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distinction between benign and \"malignant\" GCT may be difficult since the transformed element (atypical cells) may be relatively difficult to detect in a \"sea\" of reactive giant cells. This problem is exacerbated by the sampling limitations that are inherent in the use of core or fine needle biopsies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Histogenesis and molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histogenesis of GCTB is incompletely understood. While it is currently believed that the neoplastic component of GCT is derived from the stromal compartment, the specific cellular origin remains uncertain. The stromal cells show no cytologic features of malignancy. This fact, along with the inability of the stromal cells to form clones in semisolid medium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/40,43\">",
"     40,43",
"    </a>",
"    ], and the lack of clonal cytogenetic structural aberrations in GCTB in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/26,37,44\">",
"     26,37,44",
"    </a>",
"    ] has led some to question whether GCTB represents a true neoplasm or a reactive condition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in support of a neoplastic etiology, at least one array-based comparative genomic hybridization study has identified 20q11 amplifications in 54 percent of GCTBs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/46\">",
"     46",
"    </a>",
"    ]. Centrosome amplification has been described in GCTB, and appears correlated with recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/47\">",
"     47",
"    </a>",
"    ]. Furthermore, increased telomerase activity and prevention of shortening of the telomeres have been commonly reported in GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/48\">",
"     48",
"    </a>",
"    ]. Data suggest over-expression of p53 in 20 percent of GCTB, consistent with mutation of this gene, and which was associated with increased risk of recurrence and metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/49\">",
"     49",
"    </a>",
"    ]. These molecular features are generally considered \"proof\" of the neoplastic nature of a neoplasm. This remains the subject of research.",
"   </p>",
"   <p>",
"    RANKL (Receptor Activator of Nuclear factor Kappa B [NF-kB] Ligand) appears to be critical to the pathogenesis of GCTB. Under normal physiologic conditions, osteoclast formation requires an interaction with cells of the osteoblastic lineage, which may depend upon cell-cell contact, and the interaction of RANKL (a member of the tumor necrosis factor [TNF] ligand family, which is also known as osteoclast differentiation factor [ODF] or TRANCE, MIM 602642) with its receptor RANK [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. RANK is highly expressed on monocytes, while its ligand, RANKL, is expressed by a variety of cell types, including stromal cells and lymphocytes. A variety of coregulatory molecules also participate in osteoclast formation, including monocyte-colony stimulating factor (CSF1), vitamin D, parathyroid hormone and parathyroid hormone-related protein, and prostaglandins. The subject of skeletal development is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies identify RANKL as highly expressed by the stromal cells within a GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/37,41,53,54\">",
"     37,41,53,54",
"    </a>",
"    ]. The stromal cells also appear to secrete factors that can prevent or regulate osteoclastogenesis; this includes osteoprotegerin which blocks",
"    <span class=\"nowrap\">",
"     osteoblast/osteoclast",
"    </span>",
"    interaction and functions as a secreted natural negative regulator of RANKL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/36,51\">",
"     36,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is thought that RANKL expression by the osteoblast-like mononuclear stromal cells stimulates recruitment of the osteoclastic cells from normal monocytic pre-osteoclast cell. The osteoclastic giant cells then actively absorb host bone via a cathepsin K- and matrix metalloproteinase 13-mediated process, which would account for the osteolysis associated with these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/36,55,56\">",
"     36,55,56",
"    </a>",
"    ]. The most compelling data supporting the importance of RANKL signaling to the pathogenesis of GCTB comes from a seminal phase II trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    which provides proof of concept that interdicting RANKL signaling is a powerful and effective strategy in this disease. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'RANKL inhibitors: Denosumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, many questions remain. The underlying basis for the high levels of expression of RANKL by the stromal cell has not been clarified, since it does not appear that there is amplification or translocation of the RANKL gene (which is at the chromosome 13q14 locus). Data suggest that the transcription factor",
"    <span class=\"nowrap\">",
"     CCAAT/enhancer",
"    </span>",
"    binding protein beta",
"    <span class=\"nowrap\">",
"     (C/EBPbeta)",
"    </span>",
"    is over-expressed and regulates RANKL, but it is unclear what drives",
"    <span class=\"nowrap\">",
"     C/EBPbeta",
"    </span>",
"    expression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/57\">",
"     57",
"    </a>",
"    ]. Noonan syndrome, variants of which are associated with giant cell-rich lesions, are reported linked to germline mutations in the PTPN11 or the SOS1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A link to RANKL expression has not been reported.",
"   </p>",
"   <p>",
"    Furthermore, it is thought that there is in vivo signal or factor that must be present to stimulate the expression of RANKL by the stromal cells since isolation of stromal cells from GCTB in vitro results in rapid loss of expression of RANKL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/37\">",
"     37",
"    </a>",
"    ]. Finally, although it is thought that RANKL is being secreted by the stromal cells, our laboratory has shown higher levels of expression of RANKL in the osteoclast-associated cultures than in purified stromal cells derived from GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the possibilities put forth to explain these discrepancies is that the neoplastic stromal cell may represent an immature osteoblast phenotype, part of whose transcriptional repertoire includes RANKL, in addition to other markers of the early osteoblast lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/41\">",
"     41",
"    </a>",
"    ]. It is also postulated that the stromal cells have become activated not as a result of some inherent genetic change but instead from local hemorrhage-induced release of red cells and plasma proteins into the matrix.",
"   </p>",
"   <p>",
"    Finally, the complex relationship between the two dominant cell types within GCT is not well understood, and it is possible that unidentified reciprocal signals from the giant cells may be involved in maintaining the immature state of the stromal cell.",
"   </p>",
"   <p>",
"    While there is much remaining to be learned about the molecular pathogenesis of GCTB, the insights gained to date have led to the identification of RANKL as a major molecular target for therapy. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'RANKL inhibitors: Denosumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the treatment of choice for a resectable giant cell tumor of bone (GCTB). Options for surgical treatment include intralesional curettage (alone or followed by filling of the defect with bone cement with or without bone grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/60\">",
"     60",
"    </a>",
"    ]), marginal excision, a wide local excision, or en bloc resection with or without reconstructive surgery. The type of surgery chosen depends on the site and size of the tumor in relation to surrounding structures and tumor extent, and whether or not a pathologic fracture has occurred which may compromise reconstructive options [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reported rates of local recurrence vary substantially depending on the extent of resection and whether or not an adjuvant was used in conjunction with intralesional curettage (see below). It is generally accepted that the status of the surgical resection margins is the single best predictor of outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/15,63\">",
"     15,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    En bloc or wide local excision is associated with the lowest recurrence rates. Recurrence rates with intralesional curettage alone are as high as 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/15,64-66\">",
"     15,64-66",
"    </a>",
"    ], and may be even higher in certain sites such as the distal radius and proximal femur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/67\">",
"     67",
"    </a>",
"    ]. The inherently greater risk of local recurrence after curettage alone must be weighed against the likelihood of later successful treatment of a recurrence, and the functional defect and later risks associated with large resections [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Except for the proximal fibula or distal ulna, en bloc or wide margin resections necessitate major articular reconstruction with loss of function. Thus, these procedures cannot be recommended as standard given the usually benign behavior of GCTB, and the high rates of local control when intralesional curettage is combined with an adjuvant such as bone cement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/63,66\">",
"     63,66",
"    </a>",
"    ]. En bloc excision is generally reserved for cases involving the proximal fibula or distal ulna, a second or later recurrence, and some cases presenting with a pathologic fracture (see below).",
"   </p>",
"   <p>",
"    In some series, recurrence rates are low with curettage alone in patients whose tumors are confined to bone, but higher in those with extraosseous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/70\">",
"     70",
"    </a>",
"    ]. Because of this, lesions with extraosseous extension (ie, Campanacci grade III lesions, (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Classification'",
"    </a>",
"    above)) have been traditionally treated with en bloc resection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Some data support the view that GCTB with extraosseous extension can be successfully treated with intralesional curettage in conjunction with cementing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/61,62,74\">",
"     61,62,74",
"    </a>",
"    ], but this is not a widespread approach.",
"   </p>",
"   <p>",
"    In some series, pathologic fracture has been a risk factor for local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/17,75\">",
"     17,75",
"    </a>",
"    ], leading some to suggest that intralesional surgery (curettage) should be avoided in such cases. Management of these patients must be individualized depending upon the nature of the fracture and the implications for reconstruction. En bloc resection is generally recommended if the articular surface is grossly damaged or if there is a dislocated intraarticular fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Local adjuvants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to decrease local recurrence rates after intralesional curettage, various surgical adjuvant therapies have been tried. Examples include the use of bone cement (polymethylmethacrylate, PMMA) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/17,64,68\">",
"     17,64,68",
"    </a>",
"    ], aqueous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32146?source=see_link\">",
"     zinc chloride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/76\">",
"     76",
"    </a>",
"    ], phenol [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/77,78\">",
"     77,78",
"    </a>",
"    ], cryotherapy with or without cement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/65,79,80\">",
"     65,79,80",
"    </a>",
"    ], argon beam coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/28\">",
"     28",
"    </a>",
"    ], and the use of a high-speed burr to remove peritumoral bone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/10,81\">",
"     10,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials to support benefit of a local adjuvant over curettage alone. In contemporary retrospective series of patients treated with intralesional curettage with a local adjuvant, local recurrence rates are 13 to 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/17,61,65,82\">",
"     17,61,65,82",
"    </a>",
"    ], which compare favorably with those seen following wide local excision. However, a large series suggested no benefit from the use of local adjuvants, provided there is adequate surgical tumor removal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also no trials comparing outcomes with different adjuvant approaches. However, bone cement has emerged as the preferred adjuvant agent. Filling the cavity with bone cement allows immediate weight bearing, and the heat induced during the setting of the cement is thought to kill any remaining tumor cells, thus decreasing the risk of a local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Furthermore, the radiologic features of a cement-filled cavity are ideal to permit early identification of local recurrences.",
"   </p>",
"   <p>",
"    The beneficial effect of filling the curettage cavity with cement was shown in a retrospective series from the Scandinavian sarcoma group [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/17\">",
"     17",
"    </a>",
"    ]. Among patients undergoing intralesional surgery, recurrence rates were significantly lower in the 147 patients who had the cavity filled with cement compared to the 47 who had intralesional surgery without cementing (22 versus 56 percent). Among the 27 patients who had intralesional surgery followed by filling of the cavity with a bone graft only, the local recurrence rate was 61 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, these data suggest that intralesional surgery (curettage) is the treatment of choice for potentially resectable intraosseous GCTB. Packing of the cavity with an adjuvant such as bone cement decreases the risk of a local recurrence. Indications for more extensive surgery include extraosseous extension, tumor involving the proximal fibula or distal ulna, a dislocated pathologic fracture, or one in which the articular surface is grossly damaged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Management of local recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three fourths of all local recurrences develop within two years, and the remainder within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/17,75,86,87\">",
"     17,75,86,87",
"    </a>",
"    ]. Thus, surveillance beyond five years is not needed, except for monitoring of functional outcomes, especially following reconstructive surgery.",
"   </p>",
"   <p>",
"    In general, locally recurrent potentially resectable GCTB can be successfully treated by further curettage and local adjuvant therapy with only a minor risk of increased morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/69,86,88\">",
"     69,86,88",
"    </a>",
"    ]. More extensive surgery is indicated for a second or later recurrence. For patients with unresectable locally recurrent disease, options include radiation therapy, arterial embolization, and systemic therapy.",
"   </p>",
"   <p>",
"    Given that most cases of pulmonary metastases develop in patients who have locally recurrent disease, a screening chest CT is reasonable in the setting of a local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Pulmonary metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;GCTB is a radiosensitive tumor, and radiotherapy is highly effective, resulting in long-term local control rates ranging from 60 to 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/31,89-94\">",
"     31,89-94",
"    </a>",
"    ]; lower rates are reported for tumors &gt;8.5 cm and for locally recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/89,93\">",
"     89,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiotherapy is a reasonable option if surgery is contraindicated, or in a situation where negative surgical margins can only be achieved with unacceptable morbidity. One example of where this might be the case is a large midline sacral GCTB. Resection of a small sacral tumor to one side of midline may be possible without unacceptable morbidity if one set of sacral nerves can be preserved, providing reasonable postoperative bladder and bowel function. However, a complete resection of a large midline sacral GCTB would necessitate sacrifice of both sets of sacral nerves, leading to permanent double incontinence.",
"   </p>",
"   <p>",
"    Radiation has also been used as an adjuvant therapy to reduce local recurrence rates after intralesional surgery for spinal GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. There are no trials comparing radiation therapy versus a local adjuvant such as bone cement or burring in this setting.",
"   </p>",
"   <p>",
"    Given the young age of most of these patients, a major concern with RT is the risk of radiation-induced malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/91,97,98\">",
"     91,97,98",
"    </a>",
"    ]. The magnitude of the risk of not known. While several reports cite no increased risk of malignancy in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/90,92,99-101\">",
"     90,92,99-101",
"    </a>",
"    ], at least one series notes an 11 percent risk of radiation-induced sarcoma among patients undergoing radiotherapy for a primary or recurrent GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/102\">",
"     102",
"    </a>",
"    ]. An important point is that these series included patients treated with older orthovoltage radiation techniques where the doses absorbed by bone would have been substantially higher than the prescription dose. Lower rates are expected with modern megavoltage irradiation. Newer techniques, such as intensity modulated radiotherapy, appear promising but data are preliminary at this stage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sacral tumors and arterial embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, large midline GCTB of the sacrum are difficult to treat. Surgery carries a high risk of morbidity and disability, and radiation carries at least the potential risk of long-term malignant transformation. Successful treatment with arterial embolization has been described, although published experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pulmonary metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local recurrence is accompanied by an increased risk of \"benign\" pulmonary implants. In many series, all cases of lung metastases follow a local recurrence, however, this is not a universal finding. In a series of 470 patients with GCTB diagnosed over a 20-year period at Tata Memorial Hospital in India, 24 developed distant metastases, 21 involving lung [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/8\">",
"     8",
"    </a>",
"    ]. Only 13 had a local recurrence before or at the time of metastatic spread. Other involved sites were scalp, the calf muscle, and regional lymph nodes.",
"   </p>",
"   <p>",
"    The clinical outcomes of patients with pulmonary metastasis generally remain consistent with the generally benign character of the tumor. However, fatal cases are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/10\">",
"     10",
"    </a>",
"    ]. Spontaneous regression of pulmonary metastases is also described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/24,106,107\">",
"     24,106,107",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Given the uncertainty as to the natural history of pulmonary metastases, some centers simply observe these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. However, surgical resection is more often recommended, mainly because of the possibility of a fatal outcome, and the fact that untreated pulmonary metastases can cause hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/8\">",
"     8",
"    </a>",
"    ]. If observation is chosen, close monitoring with chest CT is needed for early detection of tumor progression.",
"   </p>",
"   <p>",
"    Prognosis after surgical removal is usually good [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/8,106,108,110,111\">",
"     8,106,108,110,111",
"    </a>",
"    ], but the individual course remains unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some advocate low-dose whole lung radiotherapy for patients with pulmonary metastases who are poor surgical candidates or who refuse thoracic surgery, those whose disease is technically unresectable, or if disease recurs or progresses after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/82\">",
"     82",
"    </a>",
"    ]. Another option for these patients is treatment with the RANKL inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , at present available only through participation on a therapeutic trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'RANKL inhibitors: Denosumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Chemotherapy and interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various studies report the use of cytotoxic chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) in unresectable advanced GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/24,26,30,113-116\">",
"     24,26,30,113-116",
"    </a>",
"    ] (and in some cases for extraosseous tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/117\">",
"     117",
"    </a>",
"    ]), but none are randomized trials. Given the generally benign nature of the disease and the efficacy and tolerability of other forms of treatment, chemotherapy is not generally considered a standard approach, except for a true malignant GCTB.",
"   </p>",
"   <p>",
"    Interferon has been used for treatment of \"aggressive\" disease but is associated with significant side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. While anecdotal data suggest antitumor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/10,118,119\">",
"     10,118,119",
"    </a>",
"    ], in the absence of randomized studies, the utility of interferon remains unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies suggest that bisphosphonates may be effective in killing the stromal and osteoclast-like cells of GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. A few clinical reports note symptomatic benefit and local disease control, sometimes for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. However, eradication of tumor giant cells has not been observed following preoperative treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/122,124\">",
"     122,124",
"    </a>",
"    ], and the role of bisphosphonates in the clinical care of patients with GCTB remains to be clearly defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     RANKL inhibitors: Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, RANKL appears to be critical to the pathogenesis of GCTB. The development of highly specific agents that target RANKL has generated substantial interest in molecularly targeted therapy for this disease. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Histogenesis and molecular pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a fully human monoclonal antibody against RANKL. Benefit in patients with GCTB was shown in a phase II study in which 37 patients with recurrent or unresectable GCTB were treated with denosumab 120 mg subcutaneously every 28 days, with two additional loading doses on days 8 and 15 of the first month [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/125\">",
"     125",
"    </a>",
"    ]. Thirty patients (86 percent) had an objective response to therapy, which was defined as either &ge;90 percent elimination of giant cells on histologic evaluation or no radiographic progression of the target lesion up to week 25. There was also sustained suppression of markers of bone turnover, as early as 28 days after the first dose, and sustained for the duration of the study, and a reduction in uptake of fluorodeoxyglucose (FDG), suggesting that PET may be an early and sensitive marker for clinical response in GCTB.",
"   </p>",
"   <p>",
"    Treatment was well tolerated in general. Although adverse events were reported in 33 patients (89 percent), the most common were pain in an extremity (n = 7), back (n = 4), or headache (n = 4). Of the five adverse effects of grade 3 or higher, only one was thought to be treatment-related (grade 3 increase in human chorionic gonadotropin not related to pregnancy).",
"   </p>",
"   <p>",
"    These data suggest that interdicting RANKL signaling is an effective strategy in this disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is not registered for this indication at present in any country, although it is approved for treatment of osteoporosis in the United States. A global clinical trial protocol is available evaluating the use of denosumab in patients with advanced or selected resectable GCTB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/112\">",
"     112",
"    </a>",
"    ]. Whether denosumab can be used to decrease local recurrences is not known, and the role of this drug in the adjuvant setting is under study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of Paget disease with extraskeletal giant cell tumors, there are some data indicating local control with steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. Control of GCTB growth using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    injected locally into the tumor is also reported to be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell tumor of bone (GCTBs) is a benign but locally aggressive bone tumor that typically presents as a lytic lesion in the epiphyseal region of long bones in young adults, usually around the knee. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical behavior of GCTB is unpredictable. Although they are considered benign lesions, they tend to recur locally after simple curettage and can even metastasize. Pulmonary metastases do not carry the same grave prognosis as is seen with other tumors, as reflected by their designation as \"benign\" pulmonary implants. Rarely, GCT undergoes primary malignant change. There are no clinical, histologic, or radiographic parameters that can accurately predict aggressive behavior. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the treatment of choice for a GCTB. For potentially resectable intraosseous lesions (primary or recurrent), we recommend intralesional curettage followed by filling of the cavity with bone cement (polymethylmethacrylate, PMMA) rather than curettage alone (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Indications for more extensive surgery include extraosseous extension, tumor involving the proximal fibula or distal ulna, a second or later recurrence, a dislocated pathologic fracture, or one in which the articular surface is grossly damaged.",
"   </p>",
"   <p>",
"    For patients with a GCTB at a site where surgical margins can only be achieved with unacceptable morbidity (as, for example, with a large midline sacral GCTB with no chance of preserving at least one set of sacral nerve roots), or if the patient is a poor surgical candidate, radiotherapy is a reasonable option. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For sacral tumors, another option is arterial embolization, although published experience is limited. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Sacral tumors and arterial embolization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Local recurrence is accompanied by an increased risk of pulmonary metastases. We suggest screening of such patients for pulmonary metastases with a chest CT (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Management of local recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most patients with pulmonary metastases have a favorable outcome and do not die of their disease. Nevertheless, we suggest surgery rather than observation for most patients (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). If observation is chosen, close monitoring is needed for early detection of tumor progression. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Pulmonary metastases'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Newer therapeutic agents hold promise for patients for whom local therapies are not suitable. The characterization of the role of the",
"    <span class=\"nowrap\">",
"     RANK/RANKL",
"    </span>",
"    axis in mediating the recruitment and function of osteoclast-like cells has provided a strong rationale for the use of targeted therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    which affect this pathway. Although denosumab is not yet commercially available, participation in a clinical trial evaluating the use of denosumab for recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unresectable disease is encouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?5/33/5658/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of other systemic therapies remains undefined.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cooper AS, Travers B. Surgical Essays, Cox, Longman &amp; Co, London 1818.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/2\">",
"      Jaffe HL, Portis RB. Giant Cell Tumor Of Bone. Its Pathologic Appearance, Grading. Supposed Variants and Treatment. Arch Pathology 1940; 30:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/3\">",
"      Larsson SE, Lorentzon R, Boquist L. Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968. J Bone Joint Surg Am 1975; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/4\">",
"      Baena-Ocampo Ldel C, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R. Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol 2009; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/5\">",
"      Guo W, Xu W, Huvos AG, et al. Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl) 1999; 112:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/6\">",
"      Sung HW, Kuo DP, Shu WP, et al. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am 1982; 64:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/7\">",
"      Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 2006; 30:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/8\">",
"      Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res 2010; 468:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/9\">",
"      Hoch B, Inwards C, Sundaram M, Rosenberg AE. Multicentric giant cell tumor of bone. Clinicopathologic analysis of thirty cases. J Bone Joint Surg Am 2006; 88:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/10\">",
"      Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008; 134:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/11\">",
"      Puri A, Agarwal MG, Shah M, et al. Giant cell tumor of bone in children and adolescents. J Pediatr Orthop 2007; 27:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/12\">",
"      Rendina D, Mossetti G, Soscia E, et al. Giant cell tumor and Paget's disease of bone in one family: geographic clustering. Clin Orthop Relat Res 2004; :218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/13\">",
"      Kim GS, Kim SH, Cho JK, et al. Paget bone disease involving young adults in 3 generations of a Korean family. Medicine (Baltimore) 1997; 76:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/14\">",
"      Cohen MM Jr, Gorlin RJ. Noonan-like/multiple giant cell lesion syndrome. Am J Med Genet 1991; 40:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/15\">",
"      Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987; 69:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/16\">",
"      Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. 1980. Clin Orthop Relat Res 2003; :4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/17\">",
"      Kivioja AH, Blomqvist C, Hietaniemi K, et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008; 79:86.",
"     </a>",
"    </li>",
"    <li>",
"     Reid R, Banerjee SS, Sciot R. Giant cell tumor. In: World health organization classification of tumours. Pathology and genetics. Tumours of soft tissue and bone, Fletcher CD, Unni KK, Mertens F (Eds), 2002. p.310.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/19\">",
"      Murphey MD, Nomikos GC, Flemming DJ, et al. From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics 2001; 21:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/20\">",
"      Kwon JW, Chung HW, Cho EY, et al. MRI findings of giant cell tumors of the spine. AJR Am J Roentgenol 2007; 189:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/21\">",
"      McKinney AM, Reichert P, Short J, et al. Metachronous, multicentric giant cell tumor of the sphenoid bone with histologic, CT, MR imaging, and positron-emission tomography/CT correlation. AJNR Am J Neuroradiol 2006; 27:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/22\">",
"      Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/23\">",
"      Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med 2004; 45:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/24\">",
"      Dominkus M, Ruggieri P, Bertoni F, et al. Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. Int Orthop 2006; 30:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/25\">",
"      Leichtle CI, Leichtle UG, G&auml;rtner V, et al. Multiple skeletal metastases from a giant cell tumour of the distal fibula with fatal outcome. J Bone Joint Surg Br 2006; 88:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/26\">",
"      Osaka S, Toriyama M, Taira K, et al. Analysis of giant cell tumor of bone with pulmonary metastases. Clin Orthop Relat Res 1997; :253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/27\">",
"      Domovitov SV, Healey JH. Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol 2010; 17:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/28\">",
"      Grote HJ, Braun M, Kalinski T, et al. Spontaneous malignant transformation of conventional giant cell tumor. Skeletal Radiol 2004; 33:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/29\">",
"      Brien EW, Mirra JM, Kessler S, et al. Benign giant cell tumor of bone with osteosarcomatous transformation (\"dedifferentiated\" primary malignant GCT): report of two cases. Skeletal Radiol 1997; 26:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/30\">",
"      Anract P, De Pinieux G, Cottias P, et al. Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop 1998; 22:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/31\">",
"      Ruka W, Rutkowski P, Morysi��ski T, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys 2010; 78:494.",
"     </a>",
"    </li>",
"    <li>",
"     Bullough PG, Bansal M. Malignancy in giant cell tumor. In: World health organization classification of tumours. Pathology and genetics. Tumours of soft tissue and bone, Fletcher CD, Unni KK, Mertens F (Eds), 2002. p.313.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/33\">",
"      Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer 2003; 97:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/34\">",
"      Sato K, Yamamura S, Iwata H, et al. Giant cell-rich osteosarcoma: a case report. Nagoya J Med Sci 1996; 59:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/35\">",
"      Atkins GJ, Kostakis P, Vincent C, et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006; 21:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/36\">",
"      Lau YS, Sabokbar A, Gibbons CL, et al. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005; 36:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/37\">",
"      Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005; 167:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/38\">",
"      Liao TS, Yurgelun MB, Chang SS, et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 2005; 23:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/39\">",
"      Anazawa U, Hanaoka H, Shiraishi T, et al. Similarities between giant cell tumor of bone, giant cell tumor of tendon sheath, and pigmented villonodular synovitis concerning ultrastructural cytochemical features of multinucleated giant cells and mononuclear stromal cells. Ultrastruct Pathol 2006; 30:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/40\">",
"      Salerno M, Avnet S, Alberghini M, et al. Histogenetic characterization of giant cell tumor of bone. Clin Orthop Relat Res 2008; 466:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/41\">",
"      Atkins GJ, Haynes DR, Graves SE, et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000; 15:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/42\">",
"      Ghert M, Simunovic N, Cowan RW, et al. Properties of the stromal cell in giant cell tumor of bone. Clin Orthop Relat Res 2007; 459:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/43\">",
"      Huang TS, Green AD, Beattie CW, Das Gupta TK. Monocyte-macrophage lineage of giant cell tumor of bone. Establishment of a multinucleated cell line. Cancer 1993; 71:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/44\">",
"      Schwartz HS, Jenkins RB, Dahl RJ, Dewald GW. Cytogenetic analyses on giant-cell tumors of bone. Clin Orthop Relat Res 1989; :250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/45\">",
"      Haque AU, Moatasim A. Giant cell tumor of bone: a neoplasm or a reactive condition? Int J Clin Exp Pathol 2008; 1:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/46\">",
"      Smith LT, Mayerson J, Nowak NJ, et al. 20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer 2006; 45:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/47\">",
"      Moskovszky L, Dezs&ouml; K, Athanasou N, et al. Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability. Mod Pathol 2010; 23:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/48\">",
"      Schwartz HS, Juliao SF, Sciadini MF, et al. Telomerase activity and oncogenesis in giant cell tumor of bone. Cancer 1995; 75:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/49\">",
"      Papanastassiou I, Ioannou M, Papagelopoulos PJ, et al. P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study. Orthopedics 2010; 33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/50\">",
"      Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/51\">",
"      Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 2000; 97:10905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/52\">",
"      Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/53\">",
"      Skubitz KM, Cheng EY, Clohisy DR, et al. Gene expression in giant-cell tumors. J Lab Clin Med 2004; 144:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/54\">",
"      Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000; 156:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/55\">",
"      Lindeman JH, Hanemaaijer R, Mulder A, et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004; 165:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/56\">",
"      Mak IW, Seidlitz EP, Cowan RW, et al. Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone. Hum Pathol 2010; 41:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/57\">",
"      Ng PK, Tsui SK, Lau CP, et al. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem 2010; 110:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/58\">",
"      Hanna N, Parfait B, Talaat IM, et al. SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome. Clin Genet 2009; 75:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/59\">",
"      Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002; 70:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/60\">",
"      Mankin HJ, Hornicek FJ. Treatment of giant cell tumors with allograft transplants: a 30-year study. Clin Orthop Relat Res 2005; 439:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/61\">",
"      Wang HC, Chien SH, Lin GT. Management of grade III giant cell tumors of bones. J Surg Oncol 2005; 92:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/62\">",
"      Lackman RD, Hosalkar HS, Ogilvie CM, et al. Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res 2005; 438:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/63\">",
"      Klenke FM, Wenger DE, Inwards CY, et al. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011; 469:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/64\">",
"      Arbeitsgemeinschaft Knochentumoren, Becker WT, Dohle J, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008; 90:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/65\">",
"      Khalil el SA, Younis A, Aziz SA, El Shahawy M. Surgical management for giant cell tumor of bones. J Egypt Natl Canc Inst 2004; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/66\">",
"      Klenke FM, Wenger DE, Inwards CY, et al. Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res 2011; 469:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/67\">",
"      Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/68\">",
"      Turcotte RE, Wunder JS, Isler MH, et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002; :248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/69\">",
"      Vult von Steyern F, Bauer HC, Trovik C, et al. Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian Sarcoma Group study. J Bone Joint Surg Br 2006; 88:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/70\">",
"      Prosser GH, Baloch KG, Tillman RM, et al. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res 2005; :211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/71\">",
"      Gitelis S, Mallin BA, Piasecki P, Turner F. Intralesional excision compared with en bloc resection for giant-cell tumors of bone. J Bone Joint Surg Am 1993; 75:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/72\">",
"      Labs K, Perka C, Schmidt RG. Treatment of stages 2 and 3 giant-cell tumor. Arch Orthop Trauma Surg 2001; 121:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/73\">",
"      Ward WG Sr, Li G 3rd. Customized treatment algorithm for giant cell tumor of bone: report of a series. Clin Orthop Relat Res 2002; :259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/74\">",
"      Lackman RD, Crawford EA, King JJ, Ogilvie CM. Conservative treatment of Campanacci grade III proximal humerus giant cell tumors. Clin Orthop Relat Res 2009; 467:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/75\">",
"      Haskell A, Wodowoz O, Johnston JO. Metachronous multicentric giant cell tumor: a case report and literature review. Clin Orthop Relat Res 2003; :162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/76\">",
"      Zhen W, Yaotian H, Songjian L, et al. Giant-cell tumour of bone. The long-term results of treatment by curettage and bone graft. J Bone Joint Surg Br 2004; 86:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/77\">",
"      D&uuml;rr HR, Maier M, Jansson V, et al. Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. Eur J Surg Oncol 1999; 25:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/78\">",
"      Trieb K, Bitzan P, Lang S, et al. Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001; 27:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/79\">",
"      Muramatsu K, Ihara K, Taguchi T. Treatment of giant cell tumor of long bones: clinical outcome and reconstructive strategy for lower and upper limbs. Orthopedics 2009; 32:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/80\">",
"      Malawer MM, Bickels J, Meller I, et al. Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res 1999; :176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/81\">",
"      Blackley HR, Wunder JS, Davis AM, et al. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999; 81:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/82\">",
"      Feigenberg SJ, Marcus RB Jr, Zlotecki RA, et al. Whole-lung radiotherapy for giant cell tumors of bone with pulmonary metastases. Clin Orthop Relat Res 2002; :202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/83\">",
"      Algawahmed H, Turcotte R, Farrokhyar F, Ghert M. High-Speed Burring with and without the Use of Surgical Adjuvants in the Intralesional Management of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis. Sarcoma 2010; 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/84\">",
"      Nelson DA, Barker ME, Hamlin BH. Thermal effects of acrylic cementation at bone tumour sites. Int J Hyperthermia 1997; 13:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/85\">",
"      Leeson MC, Lippitt SB. Thermal aspects of the use of polymethylmethacrylate in large metaphyseal defects in bone. A clinical review and laboratory study. Clin Orthop Relat Res 1993; :239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/86\">",
"      Balke M, Ahrens H, Streitbuerger A, et al. Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol 2009; 135:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/87\">",
"      Ghert MA, Rizzo M, Harrelson JM, Scully SP. Giant-cell tumor of the appendicular skeleton. Clin Orthop Relat Res 2002; :201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/88\">",
"      von Steyern FV, Kristiansson I, Jonsson K, et al. Giant-cell tumour of the knee: the condition of the cartilage after treatment by curettage and cementing. J Bone Joint Surg Br 2007; 89:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/89\">",
"      Caudell JJ, Ballo MT, Zagars GK, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 2003; 57:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/90\">",
"      Chakravarti A, Spiro IJ, Hug EB, et al. Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg Am 1999; 81:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/91\">",
"      Feigenberg SJ, Marcus Jr RB, Zlotecki RA, et al. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res 2003; :207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/92\">",
"      Malone S, O'Sullivan B, Catton C, et al. Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys 1995; 33:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/93\">",
"      Miszczyk L, Wydma��ski J, Spindel J. Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys 2001; 49:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/94\">",
"      Hug EB, Muenter MW, Adams JA, et al. 3-D-conformal radiation therapy for pediatric giant cell tumors of the skull base. Strahlenther Onkol 2002; 178:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/95\">",
"      Junming M, Cheng Y, Dong C, et al. Giant cell tumor of the cervical spine: a series of 22 cases and outcomes. Spine (Phila Pa 1976) 2008; 33:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/96\">",
"      Kanamori M, Ohmori K. Curettage and radiotherapy of giant cell tumour of the sacrum: a case report with a 10-year follow-up. J Orthop Surg (Hong Kong) 2005; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/97\">",
"      Luther N, Bilsky MH, H&auml;rtl R. Giant cell tumor of the spine. Neurosurg Clin N Am 2008; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/98\">",
"      Huvos AG, Woodard HQ. Postradiation sarcomas of bone. Health Phys 1988; 55:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/99\">",
"      Nair MK, Jyothirmayi R. Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1999; 43:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/100\">",
"      Bennett CJ Jr, Marcus RB Jr, Million RR, Enneking WF. Radiation therapy for giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1993; 26:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/101\">",
"      Schwartz LH, Okunieff PG, Rosenberg A, Suit HD. Radiation therapy in the treatment of difficult giant cell tumors. Int J Radiat Oncol Biol Phys 1989; 17:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/102\">",
"      Leggon RE, Zlotecki R, Reith J, Scarborough MT. Giant cell tumor of the pelvis and sacrum: 17 cases and analysis of the literature. Clin Orthop Relat Res 2004; :196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/103\">",
"      Roeder F, Timke C, Zwicker F, et al. Intensity modulated radiotherapy (IMRT) in benign giant cell tumors--a single institution case series and a short review of the literature. Radiat Oncol 2010; 5:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/104\">",
"      Lin PP, Guzel VB, Moura MF, et al. Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer 2002; 95:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/105\">",
"      Lackman RD, Khoury LD, Esmail A, Donthineni-Rao R. The treatment of sacral giant-cell tumours by serial arterial embolisation. J Bone Joint Surg Br 2002; 84:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/106\">",
"      Siebenrock KA, Unni KK, Rock MG. Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br 1998; 80:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/107\">",
"      Kay RM, Eckardt JJ, Seeger LL, et al. Pulmonary metastasis of benign giant cell tumor of bone. Six histologically confirmed cases, including one of spontaneous regression. Clin Orthop Relat Res 1994; :219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/108\">",
"      Sanjay BK, Kadhi SM. Giant cell tumour of bone with pulmonary metastases. A report of three cases. Int Orthop 1998; 22:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/109\">",
"      Sanjay BK, Younge DA. Giant cell tumour of metacarpal with pulmonary and skeletal metastases. J Hand Surg Br 1996; 21:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/110\">",
"      Tubbs WS, Brown LR, Beabout JW, et al. Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases. AJR Am J Roentgenol 1992; 158:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/111\">",
"      Cheng JC, Johnston JO. Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. Clin Orthop Relat Res 1997; :205.",
"     </a>",
"    </li>",
"    <li>",
"     clinicaltrials.gov/ct2/show/NCT00680992?term=denosumab&amp;cond=Giant+cell+tumor+of+bone&amp;rank=1 (Accessed on March 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/113\">",
"      Bertoni F, Present D, Enneking WF. Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am 1985; 67:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/114\">",
"      Faisham WI, Zulmi W, Halim AS, et al. Aggressive giant cell tumour of bone. Singapore Med J 2006; 47:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/115\">",
"      Maloney WJ, Vaughan LM, Jones HH, et al. Benign metastasizing giant-cell tumor of bone. Report of three cases and review of the literature. Clin Orthop Relat Res 1989; :208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/116\">",
"      Stewart DJ, Belanger R, Benjamin RS. Prolonged disease-free survival following surgical debulking and high-dose cisplatin/doxorubicin in a patient with bulky metastases from giant cell tumor of bone refractory to \"standard\" chemotherapy. Am J Clin Oncol 1995; 18:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/117\">",
"      Skubitz KM, Manivel JC. Giant cell tumor of the uterus: case report and response to chemotherapy. BMC Cancer 2007; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/118\">",
"      Kaiser U, Neumann K, Havemann K. Generalised giant-cell tumour of bone: successful treatment of pulmonary metastases with interferon alpha, a case report. J Cancer Res Clin Oncol 1993; 119:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/119\">",
"      Kaban LB, Troulis MJ, Wilkinson MS, et al. Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg 2007; 65:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/120\">",
"      Cheng YY, Huang L, Kumta SM, et al. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol 2003; 27:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/121\">",
"      Chang SS, Suratwala SJ, Jung KM, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res 2004; :103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/122\">",
"      Tse LF, Wong KC, Kumta SM, et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008; 42:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/123\">",
"      Arpornchayanon O, Leerapun T. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thai 2008; 91:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/124\">",
"      Balke M, Campanacci L, Gebert C, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer 2010; 10:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/125\">",
"      Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/126\">",
"      De Chiara A, Apice G, Fazioli F, et al. Multicentric giant cell tumor with viral-like inclusions associated with Paget's disease of bone: a case treated by steroid therapy. Oncol Rep 1998; 5:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/127\">",
"      Ziambaras K, Totty WA, Teitelbaum SL, et al. Extraskeletal osteoclastomas responsive to dexamethasone treatment in Paget bone disease. J Clin Endocrinol Metab 1997; 82:3826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/33/5658/abstract/128\">",
"      Mohanty S, Jhamb A. Central giant cell lesion of mandible managed by intralesional triamcinolone injections. A report of two cases and literature review. Med Oral Patol Oral Cir Bucal 2009; 14:E98.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7731 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FC5DC09734-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5658=[""].join("\n");
var outline_f5_33_5658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION AND IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Imaging workup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HISTOLOGY, HISTOGENESIS, AND MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Histogenesis and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Local adjuvants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Management of local recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sacral tumors and arterial embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pulmonary metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Chemotherapy and interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - RANKL inhibitors: Denosumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7731\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7731|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/53/23391\" title=\"figure 1\">",
"      Components of a long bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/34/13864\" title=\"figure 2\">",
"      Bone tumor locations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_33_5659="Helpful clues in recognizing HP";
var content_f5_33_5659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Helpful clues in the recognition of hypersensitivity pneumonitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        History of recurrent atypical pneumonia, particularly if there is regularity to the illness (eg, only in spring or fall, only certain time of week or following certain events)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms developed after moving to new job or home",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient or any family member has pets (especially birds), even if the patient denies contact with the pets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of water damage to home or office, particularly to crawl space, basement, roof, ceiling tiles, carpet (even if previously cleaned)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of hot tub, sauna, swimming pool",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other people have similar symptoms or have left work because of recurrent symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient feels better when away from home or work (such as after a vacation)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5659=[""].join("\n");
var outline_f5_33_5659=null;
var title_f5_33_5660="AIDS case definition";
var content_f5_33_5660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AIDS surveillance case definitions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        CD4 cell categories",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Clinical categories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        A- Asymptomatic, PGL or acute HIV infection",
"       </td>",
"       <td class=\"subtitle2\">",
"        B*- Symptomatic (not A or C)",
"       </td>",
"       <td class=\"subtitle2\">",
"        C- AIDS indicator condition (1987)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;500/mm3 (&ge;29 percent)",
"       </td>",
"       <td>",
"        A1",
"       </td>",
"       <td>",
"        B1",
"       </td>",
"       <td>",
"        <strong>",
"         C1",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200-499/mm3 (14-28 percent)",
"       </td>",
"       <td>",
"        A2",
"       </td>",
"       <td>",
"        B2",
"       </td>",
"       <td>",
"        <strong>",
"         C2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;200/mm3 (&lt;14 percent)",
"       </td>",
"       <td>",
"        <strong>",
"         A3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         B3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         C3",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    1993 AIDS surveillance case definition for adolescents and adults. All patients in categories A3, B3, C1-C3 are reported as AIDS based upon prior AIDS-indicator conditions and/or a CD4 cell count &lt;200/mm3. AIDS-indicator conditions include three new entries added to the 1987 case definition: recurrent bacterial pneumonia, invasive cervical cancer, and pulmonary tuberculosis.",
"    <div class=\"footnotes\">",
"     * Symptomatic conditions not included in category C that (a) are attributed to HIV infection or indicate a defect in cell-mediated immunity or (b) are conditions considered to have a clinical course or to require management that is complicated by HIV infection. Examples of B conditions include but are not limited to baciliary angiomatosis; thrush; vulvovaginal candidiasis that is persistent, frequent or poorly responsive to therapy; cervical dysplasia (moderate or severe); cervical carcinoma in situ; constitutional symptoms such as fever (38.5&deg;C) or diarrhea for more than one month; oral hairy leukoplakia; and herpes zoster involving two episodes or more than one dermatome.",
"    </div>",
"    <div class=\"reference\">",
"     Data from MMWR Morb Mortal Wkly Rep 1992; 41:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5660=[""].join("\n");
var outline_f5_33_5660=null;
var title_f5_33_5661="Recommended monitoring during mitotane";
var content_f5_33_5661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F83932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F83932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended monitoring during mitotane treatment*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitotane blood level",
"       </td>",
"       <td>",
"        Every&nbsp;four to&nbsp;six weeks",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Target: 14 to 20 mg/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adverse effects",
"       </td>",
"       <td>",
"        At every visit (initially, every&nbsp;four weeks; after&nbsp;six months, every&nbsp;eight weeks)",
"       </td>",
"       <td>",
"        Gastrointestinal adverse effects: Use antiemetics (eg, metoclopramide or a 5-HT3 blocker) or loperamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ACTH",
"       </td>",
"       <td>",
"        Suspected glucocorticoid deficiency or excess",
"       </td>",
"       <td>",
"        <p>",
"         CNS side-effects (ataxia, confusion, speech or visual problems): Interrupt therapy or reduce dosage. Glucocorticoid status is difficult to determine.",
"        </p>",
"        Target: ACTH in the normal range or slightly above. Because of an increased glucorticoid clearance, high-dose glucocorticoid replacement is needed (most patients require at least 50 mg hydrocortisone per day).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum sodium and potassium",
"       </td>",
"       <td>",
"        At every visit",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24-hour urine free cortisol&nbsp;",
"       </td>",
"       <td>",
"        At every visit&nbsp;",
"       </td>",
"       <td>",
"        Aim for mid-normal range.&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GOT, GPT, bilirubin, GGT",
"       </td>",
"       <td>",
"        Initially, every&nbsp;four weeks; after&nbsp;six months, every&nbsp;eight weeks",
"       </td>",
"       <td>",
"        GGT is invariably elevated without clinical consequences. If other liver enzymes are rapidly increasing (&gt;threefold of baseline), there is risk of liver failure: Stop mitotane.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TSH, fT3, fT4",
"       </td>",
"       <td>",
"        Every three to four months",
"       </td>",
"       <td>",
"        Disturbance of thyroid hormones is frequent. Thyroid hormone replacement is recommended in patients with clinical symptoms of hypothyroidism.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testosterone",
"       </td>",
"       <td>",
"        Every&nbsp;three to four&nbsp;months",
"       </td>",
"       <td>",
"        Primary hypogonadism frequently occurs. Replacement should be initiated in patients with symptoms of hypogonadism.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renin",
"       </td>",
"       <td>",
"        Every&nbsp;six months",
"       </td>",
"       <td>",
"        If renin is elevated, add fludrocortisone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesterol (HDL, LDL), triglycerides",
"       </td>",
"       <td>",
"        Every&nbsp;three to four&nbsp;months (in an adjuvant setting)",
"       </td>",
"       <td>",
"        If LDL or HDL cholesterol are highly elevated, consider treatment with statins.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood count",
"       </td>",
"       <td>",
"        Every three to four months",
"       </td>",
"       <td>",
"        Check for relevant leucopoenia, thrombocytopoenia, and anaemia (rare).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; ACTH: adrenocorticotropic hormone; GGT: gamma glutamyltransferase; GOT: glutamic-oxaloacetic transaminase; GPT: glutamate pyruvate transaminase; TSH: thyroid-stimulating hormone; LDL: low-density lipoprotein; HDL: high-density lipoprotein.",
"     <br/>",
"     * Adapted from: Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009; 115:243.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     In the first three months, mitotane blood levels should be checked every two to three weeks. After reaching a plateau, the interval can be extended.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication.&nbsp;Zini L, Porpiglia F, Fassnact M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011; 60:1055. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5661=[""].join("\n");
var outline_f5_33_5661=null;
var title_f5_33_5662="Suture selection for facial and scalp lacerations";
var content_f5_33_5662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suture selection, anesthetic options, and time to suture removal for facial and scalp lacerations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suture material*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anesthetic",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Scalp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Galea",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        3.0 or 4.0",
"       </td>",
"       <td>",
"        Local",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin",
"       </td>",
"       <td>",
"        Staple, nonabsorbable",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , hair apposition",
"       </td>",
"       <td>",
"        Stainless steel (staples), 3.0 or 4.0 (sutures)",
"       </td>",
"       <td>",
"        Local",
"       </td>",
"       <td>",
"        7-14 days, none for hair apposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Forehead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frontalis",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        Local",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin",
"       </td>",
"       <td>",
"        Nonabsorbable",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        5.0 or 6.0 (adults), 6.0 (children)",
"       </td>",
"       <td>",
"        Local/supraorbital",
"       </td>",
"       <td>",
"        5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Cheek/face",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscle",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        Local/infraorbital",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subcutaneous",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        Local/infraorbital",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin",
"       </td>",
"       <td>",
"        Nonabsorbable",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        5.0 or 6.0 (adults), 6.0 (children)",
"       </td>",
"       <td>",
"        Local/infraorbital",
"       </td>",
"       <td>",
"        5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Eyelids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        Supra/infraorbital",
"       </td>",
"       <td>",
"        3-5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Nose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucosa",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        Local/intranasal pack",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cartilage",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        Local/intranasal pack",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        Local/intranasal pack",
"       </td>",
"       <td>",
"        3-5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Lip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscle",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        4.0 or 5.0",
"       </td>",
"       <td>",
"        Infraorbital/mental",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucosal skin",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        5.0 or 6.0 (adults), 6.0 (children)",
"       </td>",
"       <td>",
"        Infraorbital/mental",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vermillion border",
"       </td>",
"       <td>",
"        Nonabsorbable",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        Infraorbital/mental",
"       </td>",
"       <td>",
"        5 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Intraoral mucosa",
"        </strong>",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        4.0 or 5.0",
"       </td>",
"       <td>",
"        Local",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tongue",
"        </strong>",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        3.0 or 4.0",
"       </td>",
"       <td>",
"        Local",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Chin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscle",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        Local/mental",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subcutaneous",
"       </td>",
"       <td>",
"        Absorbable",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        Local/mental",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin",
"       </td>",
"       <td>",
"        Nonabsorbable",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        5.0 or 6.0",
"       </td>",
"       <td>",
"        Local/mental",
"       </td>",
"       <td>",
"        5 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Absorbable suture will resorb within 60 days. Subcutaneous absorbable sutures commonly used on facial lacerations include polyglactin 910 (Vicryl",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), poliglecaprone 25 (Monocryl",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), and polyglycolic acid (Dexon). Chromic gut is appropriate for surface sutures on mucosa. Fast-absorbing gut and, for scalp lacerations, coated polyglactin 910 [Vicryl Rapide&reg;] are appropriate for skin sutures.",
"     <br>",
"      Nonabsorbable suture will not resorb within 60 days. Nylon (Dermalon",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Ethilon",
"      <sup>",
"       &reg;",
"      </sup>",
"      ), Polybutester (Novafil",
"      <sup>",
"       &reg;",
"      </sup>",
"      ), and polypropylene (Surgilene",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Prolene",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) are commonly used.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       See \"Assessment and management of facial lacerations\", section on 'Facial nerve blocks' for instructions on how to perform supraorbital, infraorbital, and mental nerve blocks.",
"       <br>",
"        &Delta; Fast-absorbing gut or, for scalp lacerations, coated polyglactin 910 [Vicryl Rapide&reg;] may be used for skin closure without negatively impacting wound outcomes in young children to avoid the anxiety and difficulty of suture removal and in patients for whom followup for suture removal is not assured.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5662=[""].join("\n");
var outline_f5_33_5662=null;
var title_f5_33_5663="Bamboo spine in AS";
var content_f5_33_5663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bamboo spine in AS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the lumbar sacral spine in a patient with advanced ankylosing spondylitis showing a \"bamboo spine\" with vertebral fusion (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_33_5663=[""].join("\n");
var outline_f5_33_5663=null;
